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Proper maternal nutrition is critical for early embryonic development. Despite
overwhelming epidemiologic data indicating the benefits nutrient supplementation for the
developing organism we do not fully understand the genetics of predisposition to
abnormal developmental phenotypes when faced with suboptimal nutrient levels.
Copper is an essential nutrient required for critical biochemical processes. Severe
defects in copper homeostasis lead to significant disease typified by the X-linked
recessive disorder Menkes disease. Patients with Menkes disease have cutis laxa, bone
deformities, hypopigmentation, arterial malformation, and neurodegeneration due to
copper deficiency caused by loss-of-function mutations in ATP7A, a copper transport
protein. Despite the critical requirement for adequate copper nutrition and the
characterization of key copper transport proteins there remain significant gaps in our
understanding of copper metabolism.
In order to better understand both the cell metabolic and developmental
requirements for copper our laboratory has defined a zebrafish model of severe copper
deficiency. The copper chelator neocuproine causes a Menkes-like phenotype in wildii

type zebrafish embryos and the mutant calamity which phenocopies neocuproine treated
embryos contains a null allele of atp7a.
In this thesis we build upon this previous model in two ways in order to address
the problem of treatment of Menkes disease and to define novel pathways important for
copper metabolism. The first body of work uses small-molecule modifiers of mRNA
processing (morpholinos) to correct splicing defects which cause Menkes disease
phenotypes in zebrafish embryos. Since about 20% of human disease causing mutations
are due to splicing defects this approach may be directly applicable to a wide array of
human diseases. The second body of work uses a forward chemical-genetic screen for
zebrafish mutants sensitive to mild copper deficiency. Screening mutagenized embryos
exposed to subthreshold doses of the chelator neocuproine for copper deficiency
phenotypes resulted in two mutants. The first, containing a hypomorphic allele of atp7a
demonstrates the effect of maternal nutrition and genetics on embryonic development.
The second contains a loss-of-function mutation in the vacuolar proton pump leading to a
severe embyronic lethal phenotype which is sensitive to copper chelation. This implicates
pH gradients in the metabolism of copper in zebrafish.
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Purpose of review
Reports of the neurologic findings in adults with acquired copper deficiency as well as
the development of novel models for Menkes disease have permitted a greater
understanding of the role of copper in the central nervous system. A role of mitochondrial
copper homeostasis in cellular energy metabolism suggests roles for this metal in cellular
differentiation and biochemical adaptation.
Recent findings
Acquired copper deficiency in adults is reported with increasing frequency, often without
any identifiable cause. Chemical genetic studies identified a zebrafish model of Menkes
disease that can be used for high-throughput therapeutics and revealed a hierarchy of
copper distribution during development. Studies in mice reveal that the copper transport
protein Ctr1 is essential for intestinal copper absorption and suggest a unique role for
copper in axonal extension, excitotoxic cell death and synaptic plasticity in the central
nervous system. Lastly, recent biochemical studies indicate a central role for the
mitochondrial matrix in cellular copper metabolism.
Summary
The recent developments in our understanding of copper deficiency and copper
homeostasis outlined in this review provide an exciting platform for future investigations
intended to elucidate the role of copper in central nervous system development and
disease.

Introduction

3

Copper is an essential nutrient in humans, readily available in the diet and rapidly
absorbed through the stomach and duodenum into the portal circulation for subsequent
uptake by the liver. When incorporated into specific cuproenzymes, copper serves as a
critical cofactor, catalyzing the facile electron transfer reactions required for cellular
respiration, iron oxidation, pigment formation, neurotransmitter biosynthesis, antioxidant
defense, peptide amidation, and connective tissue formation (Balamurugan and
Schaffner, 2006). The liver serves as the predominant organ of copper storage and the
only physiological mechanism of copper elimination is through excretion into the bile.
Hepatic copper stores are easily depleted if copper intake is impaired by dietary copper
deficiency or malabsorption and thus copper deficiency can develop under such
circumstances (Schilsky and Fink, 2006). Although loss of cuproenzyme function
accounts for the signs and symptoms of copper deficiency, there are several clinical
findings in copper deficient patients that are not readily attributable to loss of activity of
known enzymes, suggesting either novel functions for known cuproenzymes, the
presence of as yet unidentified enzymes or unique physiological roles for copper.

Physiology of copper deficiency
Copper can enter cells via Ctr1, a high affinity polytopic membrane transport
protein found in most tissues. Previous studies in a mouse model of Ctr1 deficiency
revealed a critical role for this protein in embryonic development but early lethality
precluded definitive analysis of the role of Ctr1 in copper physiology. The Thiele group
has recently addressed this issue through the generation of intestinal epithelial cellspecific Ctr1 knockout mice. These mice are profoundly copper deficient and exhibit
4

striking neonatal defects in copper accumulation in most tissues. By a few weeks of age
these mice demonstrate severe cardiac hypertrophy, marked growth impairment and
increased mortality (Nose et al., 2006a). These defects can be overcome by
administration of parenteral copper treatment, demonstrating the essential role of Ctr1 in
intestinal copper uptake critical for early postnatal development in the mouse. These
findings are supported by recent studies in suckling mice from copper-adequate or
deficient dams that reveal that Ctr1 expression is increased in the intestine following
perinatal copper deficiency (Kuo et al., 2006). Although the mechanisms of increased
Ctr1 expression have not yet been determined, these findings are consistent with a critical
role for this transporter in intestinal copper acquisition. These studies of Ctr1 are critical
to our understanding of human copper deficiency and strongly suggest that this
transporter is required for apical membrane enterocyte copper uptake in the human
intestine. The 6-angstrom projection structure of human Ctr1 based upon electron
crystallography of two dimensional protein crystals in a native phospholipid barrier
reveals the formation of a putative pore for metal ions at the interface of three identical
subunits and reveals a novel architecture not previously described for other transport
proteins (Aller and Unger, 2006). This protein structure is based upon a Ctr1 trimer and is
structurally most closely related to channel proteins, suggesting a novel mechanism for
copper entry across membranes (Nose et al., 2006b). Understanding the precise
mechanisms by which Ctr1 transports copper will be critical for our understanding of
acquired copper deficiency in adults where functions of environmental dietary factors
such as zinc may directly interact with Ctr1 and thus disrupt intestinal copper uptake.
Such knowledge may also be critical in the design of therapeutics such as cis-platin
5

compounds that utilize this transporter for cellular uptake (Nose et al., 2006b). Inherited
polymorphismin the gene encoding human Ctr1 might be predicted to account for
variations in copper uptake amongst individuals and here again detailed structural
information may be of great value in interpreting the molecular outcome of these genetic
variants.

Acquired copper deficiency in adults
Acquired copper deficiency in adults may occur following increased zinc intake,
long-term parenteral nutrition or malabsorption from a variety of causes. The most
commonly reported manifestations of copper deficiency are hematological and may
include neutropenia, thrombocytopenia and anemia. Most recently increasing numbers of
patients have been identified with acquired copper deficiency of unknown etiology.
Harless and colleagues (Harless et al., 2006) describe two healthy young women with
copper deficiency of unclear cause, which resolved after copper supplementation. The
authors suggest that dietary factors, including soft drink consumption, may have been
involved and that the problem may be more widespread than is currently realized, a
concept supported by similar case reports from multiple institutions in the past few years.
Accompanying such reports has been the recognition of a syndrome of adult-onset copper
deficiency with neurological manifestations (Kumar et al., 2004). Affected individuals
present with sensory ataxia, hyperreflexia and a spastic gait similar to the progressive
ataxic myelopathy in goats and sheep raised on copper-deficient diets. If detected early,
copper supplementation always resolves the hematological manifestations and may
prevent further neurological deterioration. Neurologic recovery may, however, be slow
6

and preferentially involves the sensory symptoms. Recent studies in three copperdeficient
adults, two of whom were referred with a presumptive diagnosis of amyotrophic lateral
sclerosis, revealed progressive asymmetric weakness and electrodiagnostic findings of
proximal and distal denervation suggestive of lower motor neuron disease. Copper
replacement resulted in improvement in this weakness suggesting that the neurologic
spectrum of copper deficiency should include lower motor neuron disease (Weihl and
Lopate, 2006). The neurologic signs and symptoms of copper deficiency may be present
without the hematological manifestations and relapse has been reported on adequate
copper supplementation (Prodan et al., 2006), suggesting caution in both the diagnosis
and long-term follow-up of patients with acquired copper deficiency. While this
syndrome has been reported following recognized causes of copper deficiency including
zinc ingestion (Willis et al., 2005) and malabsorption (Everett et al., 2006; Tan et al.,
2006), it would appear that the majority of cases occur without any identifiable cause.
Increased serum concentrations of zinc have been reported in several patients even in the
absence of exogenous zinc ingestion, but this is not a universal observation and the
significance of this finding is unknown. Magnetic resonance imaging reveals increased
T2 signal in the dorsal midline cervical and thoracic cord that is reversible with
normalization of serum copper (Kumar et al., 2006). Taken together, these clinical and
radiologic findings are very similar to the subacute combined degeneration reported in
patients with vitamin B12 deficiency. Consistent with this finding, a pilot study reports
undiagnosed copper deficiency in a number of elderly patients with vitamin B12
deficiency, implying a role for copper in the pathogenesis of this disease (Prodan et al.,
2006).
7

Developmental copper deficiency and Menkes disease
Clinical and experimental data indicate that copper is essential for normal
development as copper deficiency during pregnancy results in neurologic impairment and
defects in organogenesis in multiple tissues. Menkes disease, a fatal neurodegenerative
disorder resulting in seizures, hypotonia, and failure to thrive, is due to inherited loss-offunction mutations in the gene encoding the copper-transporting ATPase atp7a. Although
affected patients exhibit signs and symptoms of copper deficiency, the mechanisms
resulting in neurologic disease remain unknown. To elucidate the mechanisms for these
defects a chemical genetic screen was undertaken in zebrafish, revealing a role for copper
in notochord formation and demonstrating a hierarchy of copper metabolism within the
developing embryo (Mendelsohn et al., 2006). A genetic screen for embryos phenocopied
by copper deficiency, identified calamity, a mutant defective in the zebrafish ortholog of
atp7a. The availability of a zebrafish model of Menkes disease permits a precise
characterization of the genesis of the developmental abnormalities associated with this
disorder and permits high-throughput chemical suppression screens for compounds of
immediate clinical relevance that restore cuproenzyme function in the setting of atp7a
deficiency. Of direct relevance to our understanding of copper deficiency in humans, the
gene dosage of atp7a in these studies was found to determine the sensitivity to copper
deprivation, revealing that the developmental hierarchy of copper metabolism is informed
by specific genetic factors (Merchant and Sagasti, 2006). These data suggest the
intriguing possibility that suboptimal copper availability due either to dietary factors or
genetic variation may contribute to structural birth defects and suggest the need for a
8

more critical analysis of copper deficiency in the setting of specific, isolated phenotypes
in the newborn infant.
Studies of a loss-of-function allele of DmATP7, the Drosophila orthologue of the
Menkes and Wilson genes, reveal that copper is essential in embryogenesis in this
organism, as well as early larval development and adult pigmentation. The data also
suggest the possibility of novel functions for this transporter in the developing larva that
may be relevant to our understanding of human copper deficiency (Norgate et al., 2006).
Characterization of the neurodevelopmental expression and localization of atp7a in the
murine brain reveals that this transporter is most abundant in the early postnatal period
and increases in specific regions localized to CA2 hippocampal pyramidal and cerebellar
Purkinje neurons (Niciu et al., 2006). In this study, atpt7a was detected in the axons of
postnatal, but not adult, optic nerve suggesting unique stage-specific roles for this
protein. The precisely regulated neurodevelopmental expression of atp7a observed in
these studies provides an important histological correlate for the limited therapeutic
window in patients with Menkes disease. Analysis of atp7a expression by this same
group within the developing olfactory system suggests a role for this transporter in axon
extension, a finding that could account for a component of the neurodegeneration in
Menkes disease (El Meskini et al., 2005). Recent analysis of global changes in gene
expression in the brain tissue from patients with Menkes disease reveals downregulation
of genes involved in myelination, energy metabolism, and translation and may offer
further insight into the pathogenesis of copper deficiency within the developing brain
(Liu et al., 2005).

9

Cell biological analysis within hippocampal neurons reveals a critical role for
atp7a in the availability of an N-methyl-D-aspartate (NMDA) receptor-dependent,
releasable pool of copper, demonstrating a unique mechanism linking copper homeostasis
and neuronal activation within the central nervous system (Schlief et al., 2005). These
findings suggest a role for copper in activity-dependent modulation of synaptic activity
and in support of this hypothesis, copper chelation exacerbates NMDAmediated
excitotoxic cell death in primary hippocampal neurons, whereas the addition of copper is
protective (Schlief et al., 2006). This protective effect of copper depends on endogenous
nitric oxide production in hippocampal neurons, demonstrating in-vivo links among
neuroprotection, copper metabolism, and nitrosylation. Atp7a is required for these
copper-dependent effects because hippocampal neurons isolated from a murine model of
Menkes disease reveal a marked sensitivity to endogenous glutamate-mediated NMDA
receptor-dependent excitotoxicity in vitro, and mild hypoxic/ischemic insult to these mice
in vivo results in significantly increased neuronal injury. Taken together, these data
reveal a unique connection between copper homeostasis and NMDA receptor activity that
is of broad relevance to the processes of synaptic plasticity and excitotoxic cell death.
The observation that copper deficiency exacerbates excitotoxic cell death reveals a
unique paradigm for neuronal injury in patients with Menkes disease and suggests a
novel approach to the treatment of intractable seizures in such patients via blockade of
excitatory neuronal pathways (Schlief and Gitlin, 2006).
Patients with Menkes disease reveal many of the classic signs and symptoms of
copper deficiency including marked connective tissue abnormalities secondary to
impaired activity of copper-dependent lysyl oxidases. Recent reports reveal that
10

metaphyseal dysplasia and fractures in such patients may be initially confused with child
abuse (Bacopoulou et al., 2006). Unusual clinical findings have also recently been
reported that include severe brachial artery aneurysms (Godwin et al., 2006) and bilateral
panlobular emphysema and pulmonary arterial hypoplasia (Grange et al., 2005) also due
to copperdependent impairment in connective tissue biosynthesis and cross-linking.
While Menkes disease is the only well defined genetic cause of copper deficiency during
human development, the recent report of a 4-month-old infant presenting with congenital
cataract, severe muscular hypotonia, developmental delay, sensorineural hearing loss and
cytochrome c oxidase deficiency with repeatedly low copper and ceruloplasmin levels
suggests the possibility of additional such disorders. Consistent with this idea, the family
history in this case revealed parental consanguinity and although genetic analysis of all
known copper genes was normal, copper histidine supplementation resulted in a
remarkable improvement of clinical symptoms, suggesting as yet unidentified proteins
controlling copper homeostasis (Horvath et al., 2005).
Intractable seizures are a universal feature in almost all patients with Menkes
disease and a recent analysis in affected children with prolonged survival defined three
stages of epilepsy development that include early focal status, followed by infantile
spasms and subsequent myoclonic and multifocal epilepsy after 2 years of life (BahiBuisson et al., 2006). These clinical observations may have relevance for the
development of treatment optimization for the severe copper deficiency observed in
Menkes disease. Iinuma and colleagues (Munakata et al., 2005) used proton magnetic
resonance spectroscopy to examine the metabolic changes in the brain of a boy with
Menkes disease treated with parenteral copper histidine supplementation from 5 months
11

of age. Therapy initiated after the critical period still improved the neuronal metabolism,
suggesting that some copper was delivered to neurons despite the fact that brain atrophy,
impaired myelination, and severe neurological symptoms were largely unaffected. In this
case and another recent report (Olivares et al., 2006) the authors hypothesize that some
correlation exists between genotype and clinical outcome after copper histidine therapy,
although this remains a very poorly understood clinical issue. The Kaler group at the US
National Institutes of Health has had considerable experience with this treatment
approach and in a thoughtful review of their experience suggest that in light of the limited
clinical benefits and potential risks, the decision whether or not to offer copperreplacement treatment to symptomatic Menkes patients represents an ethical challenge
best made in each case in consultation with the patient’s parents (Sheela et al., 2005).
While not advancing our knowledge of treatment mechanisms, this approach is welcome
and critical to the appropriate care of the family in the circumstances of such a
devastating diagnosis.

Mitochondrial copper and Sco2
Under physiological circumstances, the availability of free intracellular copper is
restricted, and therefore following uptake by Ctr1 copper is bound to a family of proteins
termed metallochaperones that function to deliver this metal to specific pathways,
protecting against intracellular copper chelation (Culotta et al., 2006). Copper trafficking
to the mitochondria is necessary for the proper metallation of cytochrome c oxidase and
requires the metallochaperones Cox17, Sco1 and Sco2 (Cobine et al., 2006b). As the
copper-binding subunits of cytochrome c oxidase are encoded by the mitochondrial
12

genome, copper insertion into this protein must occur within this organelle. Consistent
with a role for these chaperones in cytochrome c oxidase function, inherited deficiency of
Sco2 results in a fatal encephalocardiomyopathy from impaired respiratory chain function
(Bohm et al., 2006). Interestingly, a recent report examining patient and parental
genotypes identified a child with hemizygosity for the common Sco2 missense mutation
E140K, a finding with important implications for genetic counseling (Leary et al., 2006).
The relevance of these Sco2 mutations to copper deficiency has recently become more
apparent with the observation that a mitochondrial matrix copper pool serves as the
source of copper for cytochrome c oxidase metallation (Cobine et al., 2006a). Most
interestingly, this process is dependent upon a unique mitochondrial matrix copper ligand
that may serve as a sensor of copper homeostasis within cells.
Although the identity of this mitochondrial matrix copper ligand has not yet been
determined, this finding is of potential broad significance in our understanding of the
mechanisms of cellular copper homeostasis and the pathogenesis of neuronal injury in
copper deficiency. This concept is underscored by recent studies that identify Sco2 as a
critical downstream mediator between the utilization of respiratory and glycolytic
pathways in cells (Matoba et al., 2006). In this work, p53, a gene frequently mutated in
cancer, was shown to regulate Sco2 expression. Furthermore, disruption of the Sco2 gene
in cancer cells with wild-type p53 shifted metabolism toward glycolysis analogous to that
observed in p53-deficient cells. This metabolic switch to glycolysis, commonly known as
the Warburg effect, is proposed to provide a significant growth advantage to cancer cells,
permitting proliferation and possibly promoting invasive characteristics (Assaily and
Benchimol, 2006; Kruse and Gu, 2006). The finding that Sco2 is a direct metabolic target
13

of p53 reveals an essential and previously unappreciated role for copper in the regulation
of cellular energy metabolism. Although still in the early stages, such observations
suggest novel mechanisms for neuronal injury in copper deficiency directly related to the
mitochondrial regulation of aerobic respiration, energy production and metabolism.
Conclusion
Copper deficiency remains an important, albeit uncommon clinical problem.
Clinical and experimental studies in affected patients continue to reveal new insights into
the fundamental roles of copper in cellular biochemistry. Exciting new findings regarding
the role of copper in synaptic plasticity and excitotoxicity offer new therapeutic
approaches and suggest unique functions of copper in neurobiology. Lastly, observations
on the role of copper and Sco2 in mitochondrial biology may herald new insights into the
role of copper in mitochondrial biology, energy homeostasis and neurodegenerative
disease.
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Abstract
Copper and iron are transition elements essential for life. These metals are required to
maintain the brain’s biochemistry such that deficiency or excess of either copper or iron
results in central nervous system disease. This review focuses on the inherited disorders
in humans that directly affect copper or iron homeostasis in the brain. Elucidation of the
molecular genetic basis of these rare disorders has provided insight into the mechanisms
of copper and iron acquisition, trafficking, storage, and excretion in the brain. This
knowledge permits a greater understanding of copper and iron roles in neurobiology and
neurologic disease and may allow for the development of therapeutic approaches where
aberrant metal homeostasis is implicated in disease pathogenesis.
Introduction
Copper and iron function as cofactors in specific proteins, catalyzing electron
transfer reactions required for cellular metabolism and binding inorganic ions (e.g.,
oxygen) that serve as substrates for this biochemistry (Andrews and Schmidt, 2007;
Balamurugan and Schaffner, 2006). Deficiency in these metals results in metabolic
abnormalities due to loss of function of these iron- and copperdependent proteins. Excess
of these metals can result in the unregulated oxidation of proteins, lipids, and other
cellular components causing subsequent tissue injury. Thus pathways of copper and iron
metabolism have evolved to ensure adequate amounts of each metal for cellular survival
while protecting the organism from the consequences of metal excess. In the past decade,
elucidation of the genetic basis of many of the inherited copper and iron metabolism
disorders has begun to provide insight into these pathways, permitting an understanding
of the mechanisms involved in cellular homeostasis of these metals.
17

The inherited copper and iron metabolism disorders that cause deficiency or
excess of these metals in the brain result in central nervous system disease (Ponka, 2004;
Waggoner et al., 1999). Although these disorders reveal that copper and iron homeostasis
is essential for normal brain function, little is currently known about the mechanisms of
copper and iron acquisition, trafficking, storage, and excretion within the central nervous
system. How and where are iron and copper stored in the brain and under which
circumstances do these metals accumulate? How do cells in the brain acquire these
metals when needed? Why is iron deficiency in utero associated with significant longterm cognitive impairment? How are the uptake and excretion of these metals regulated
in the brain, and what is the relationship to these processes in systemic circulation? How
does excess copper accumulation within the brain result in psychiatric disease? Does
impaired homeostasis of copper or iron contribute to the pathogenesis of common
neurodegenerative disorders such as Parkinson or Alzheimer disease? One only has to
view the clinical consequences of accumulation or deficiency of these metals in the
human brain to appreciate the critical nature of such questions. Mechanistic
understanding of the human genetic disorders that impair copper or iron homeostasis in
the brain provides insight into the role of these metals in neurobiology and disease.

COPPER
Overview
Copper is required for cellular respiration, iron oxidation, pigment formation,
neurotransmitter biosynthesis, antioxidant defense, peptide amidation, and connective
tissue formation (Pena et al., 1999). This metal is essential for central nervous system
18

development, and disruption of copper homeostasis during fetal life leads to perinatal
mortality, severe growth retardation, and neurodegeneration (Keen et al., 1998).
Experiments in mice reveal that the developmental timing of perinatal copper deficiency
influences the severity of neurological outcome, suggesting a critical period for brain
copper acquisition (Prohaska and Brokate, 2002). Acquired copper deficiency in adults
results in myelopathy with lower limb spasticity and sensory ataxia due to ascending
sensory tract dysfunction and neurodegeneration of the dorsal column (Kumar et al.,
2004; Prodan et al., 2006).
Menkes disease and Wilson disease are the known inherited disorders of copper
metabolism in humans (Table 1). The essential role of copper in the developing central
nervous system is evidenced by Menkes disease, during which impaired copper transport
into and within the developing brain results in demyelination and neurodegeneration
(Kaler, 1998; Kodama et al., 1999). Brain copper accumulation inWilson disease results
in dystonia, dysarthria, and other Parkinsonian symptoms, as well as psychiatric
symptoms of depression, cognitive deterioration, personality change, psychosis, and
schizophrenia (Ferenci, 2004; Oder et al., 1991). Although the signs and symptoms of
Menkes and Wilson diseases are distinct, each disorder results from inherited loss-offunction mutations in genes encoding homologous copper-transporting P-type adenosine
triphosphatases (Atpases) Atp7a and Atp7b (Figure 1) (Culotta and Gitlin, 2001a).
Copper Metabolism
Copper is readily available in the diet and, following absorption through the
stomach and duodenum, is rapidly removed from the portal circulation by hepatocytes in
the liver. Biliary excretion is the only physiological mechanism of copper elimination,
19

and at steady state the amount of copper excreted into the bile is equivalent to that
absorbed from the intestine (Gitlin, 2003). The rate of copper excretion into the bile
increases promptly in response to an increase in dietary copper, and excess of this metal
does not occur in the absence of an underlying metabolic defect (Gollan and Deller,
1973). This aspect of copper homeostasis is critical to the interpretation of any study that
implicates increases in dietary copper content with neurologic disease (Sparks and
Schreurs, 2003).
Ctr1 is a plasma membrane protein essential for early embryonic development
and intestinal copper uptake (Kuo et al., 2001; Lee et al., 2001; Nose et al., 2006a)
(Figure 2). Ctr1 is present on endothelial cells of the bloodbrain barrier, and expression
at this site increases following perinatal copper deficiency (Kuo et al., 2006). These
observations suggest that copper is transported from the plasma into the brain via Ctr1.
Intracellular copper metabolism is dependent on the copper transport Atpases, Atp7a and
Atp7b. One of these Atpases resides in the late Golgi of every cell, delivering copper to
the secretory pathway for incorporation into cuproenzymes and excretion (Figure 1). In
the brain, Atp7a is expressed in endothelial cells of the bloodbrain barrier and facilitates
copper movement across the basolateral membrane into the extravascular space of the
brain. Atp7a is also ex- pressed within specific populations of neurons in several brain
regions including the cerebellum and hippocampus (Figure 3). Atp7b is expressed in
hepatocytes and is required for copper excretion from these cells into the bile. Copperdependent trafficking of these Atpases serves as the primary mechanism determining
intracellular copper homeostasis (Lutsenko and Petris, 2003; Petris et al., 1996) (Figure
2).
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Intracellular trafficking of copper also requires proteins termed metallochaperones
that direct this metal to specific cellular pathways (O'Halloran and Culotta, 2000; Rae et
al., 1999). These chaperones include Atox1, which delivers copper to the
coppertransporting Atpases in the late Golgi (Hamza et al., 2001; Hamza et al., 2003),
CCS, which is required for copper incorporation into cytoplasmic Cu/Zn superoxide
dismutase (Culotta et al., 2006; Wong et al., 2000), and Cox17, Sco1, and Sco2, which
deliver copper to mitochondrial cytochrome c oxidase (Hamza and Gitlin, 2002) (Figure
2). Sco1 and Sco2 also function in a pathway of mitochondrial copper homeostasis
(Leary et al., 2007). Metallothionein is a cysteine-rich cytoplasmic protein that chelates
copper and is essential to protect against the toxicity caused by excess copper (Kelly and
Palmiter, 1996).
Copper is distributed throughout most regions of the brain and is most abundant
in the basal ganglia. Studies have detected this metal in the cell bodies of cortical
pyramidal and cerebellar granular neurons, in the neuropil of the cerebral cortex, in the
hippocampus and cerebellum, and in synaptic membranes of afferent nerves (Kozma et
al., 1981; Sato et al., 1994; Trombley and Shepherd, 1996). In some neurons, copper is
released at the synapse (Brown et al., 1997; Hartter and Barnea, 1988) reaching
micromolar concentrations (Kardos et al., 1989) that can abrogate long-term potentiation
in the hippocampus (Doreulee et al., 1997). Copper is an antagonist at N-methyl- Daspartate (NMDA) receptors in cultured hippocampal neurons (Vlachova et al., 1996;
Weiser and Wienrich, 1996), modulating activation of calcium-dependent cascades that
contribute to synaptic plasticity (Lu et al., 2001). Synaptic NMDA receptor activation
results in rapid and reversible trafficking of Atp7a in cultured hippocampal neurons in
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association with copper release, suggesting the presence of a mechanism linking copper
homeostasis and neuronal activation within the brain (Schlief et al., 2005) (Figure 3).
Menkes Disease
Menkes disease is an X-linked disorder characterized by growth failure, brittle
hair, hypopigmentation, arterial tortuosity, and neuronal degeneration due to loss-offunction mutations in the gene encoding Atp7a (Chelly et al., 1993; Mercer et al., 1993;
Vulpe et al., 1993). The pleiotropic features of this disease are the result of impaired
activity of specific cuproenzymes resulting from impaired Atp7a function (Figure 2).
The neurologic features are present in early infancy, revealing a critical role for Atp7a
and copper in neuronal development (Mercer, 1998). Magnetic resonance imaging of the
brain reveals deficient myelination with cerebellar and cerebral atrophy (Geller et al.,
1997; Leventer et al., 1997), and neuropathologic examination demonstrates focal
degeneration of the gray matter and neuronal loss most prominent in the hippocampus
and cerebellum (Barnard et al., 1978; Okeda et al., 1991) (Figure 4).
Although several of the known cuproenzymes play critical roles in brain
biochemistry, the mechanisms of neurodegeneration in Menkes disease are unknown and
not explained by impaired activity of any of these enzymes (Table 2). Studies in a murine
model of Menkes disease suggest a role for Atp7a and copper in axon extension and
synaptogenesis during development (El Meskini et al., 2005). Atp7a mediates the
availability of an NMDA receptor–dependent, releasable pool of copper in hippocampal
neurons (Schlief et al., 2005), and the absence of Atp7a activity in Menkes disease
markedly accentuates NMDA receptor–mediated excitotoxicity in these neurons (Schlief
et al., 2006). These data suggest a model whereby loss of Atp7a contributes to both
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seizures and neuronal degeneration in affected patients and raise the possibility of
therapeutic approaches based on NMDA receptor blockade (Hardingham and Bading,
2003; Schlief et al., 2006).
Systemic copper treatment is not effective in patients with Menkes disease
because copper transport into the brain is dependent on Atp7a. Rare patients with some
residual Atp7a activity have less central nervous system pathology despite significant
systemic disease (Moller et al., 2000) and when treated with copper evidence
neurodevelopmental improvement (Christodoulou et al., 1998; Kaler et al., 1995). This
clinical observation reveals a hierarchy of copper distribution preferential to the brain
under circumstances of limited copper availability, a concept supported by recent
observations in a zebrafish model of Menkes disease (Mendelsohn et al., 2006). The
mechanisms of this hierarchy are unclear but this process illustrates copper’s essential
role in brain development.
Wilson Disease
Wilson disease is an autosomal recessive disorder resulting in hepatic cirrhosis
and progressive basal ganglia degeneration due to loss-of-function mutations in the gene
encoding the copper-transporter Atp7b (Bull et al., 1993; Tanzi et al., 1993; Yamaguchi
et al., 1993). The resulting impairment in biliary copper excretion leads to hepatocyte
copper accumulation, copper-mediated liver damage, activation of cell-death pathways,
leakage of copper into the plasma, and eventual copper overload in all tissues (Figure 4)
(Gitlin, 2003; Tao and Gitlin, 2003). Although Atp7b is expressed in some regions of the
brain, in Wilson disease copper overload in extrahepatic tissues is due to excess
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accumulation from the plasma following liver injury because this is entirely reversed
following liver transplantation (Emre et al., 2001; Schumacher et al., 2001).
Ceruloplasmin is an essential ferroxidase that contains greater than 95% of the
copper present in plasma. This protein is synthesized in hepatocytes and secreted into the
plasma following the incorporation of six copper atoms in the late secretory pathway. In
Wilson disease, loss of function of Atp7b results in synthesis of apoceruloplasmin that is
rapidly degraded in the plasma (Figure 5). As a result, the serum ceruloplasmin
concentration is a useful diagnostic indicator ofWilson disease (Hellman and Gitlin,
2002).
Almost half of all patients with Wilson disease present with signs and symptoms
of neuropsychiatric illness (Gollan and Gollan, 1998). Although such neurological
features may initially be subtle, without chelation patients will progress to severe
Parkinsonian symptoms, consistent with the neuropathologic findings of basal ganglia
copper accumulation and neurodegeneration (Oder et al., 1991). Neurodegeneration in
Wilson disease results directly from copper accumulation, but the precise mechanisms of
cellular injury are unknown. Psychiatric symptoms are also common and range from
behavioral problems to psychosis (Dening, 1991). These abnormalities, although without
neuropathologic correlates, are clearly the result of brain copper accumulation because
prompt improvement is observed upon treatment with oral chelating agents to restore
copper homeostasis. The reversible nature of many of these psychiatric symptoms is
consistent with the concept that copper can modulate synaptic function (Schlief and
Gitlin, 2006) and suggests novel avenues for investigation in common psychiatric
disorders.
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IRON
Overview
Iron is required as a cofactor in central nervous system metabolic processes
including oxidative phosphorylation, neurotransmitter production, nitric oxide
metabolism, and oxygen transport (Ponka, 1999). The observation that brain iron content
is increased in patients with Parkinson disease and other neurodegenerative disorders has
created significant interest in the possibility that disturbances of brain iron homeostasis
may contribute to the pathogenesis of these diseases (Thomas and Jankovic, 2004).
Although numerous clinical and experimental studies have attempted to address this
issue, a causative role for impaired iron homeostasis has yet to be established in these
more common neurodegenerative diseases. Nevertheless, interest in this neuropathology
has focused increased attention on elucidating the mechanisms of brain iron homeostasis
and on defining iron’s role in neurologic disease.
The inherited diseases of iron metabolism are more common and more numerous
than those of copper, and the genetic basis of many of these disorders has been
characterized (Andrews, 2002). Although many of the proteins shown to be essential for
systemic iron homeostasis are expressed within the brain (Wu et al., 2004; Zecca et al.,
2004), genetic disorders resulting in loss of function of these proteins rarely result in
either brain iron overload or deficiency or neurologic disease. For example, although
ferroportin is abundantly expressed in the brain microvasculature and is the only known
cellular iron exporter, patients with mutations that impair this protein’s function have no
evidence of brain iron accumulation (Pietrangelo, 2006a). These observations suggest the
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presence of unique mechanisms regulating iron metabolism within the central nervous
system.

Iron Metabolism
Genetic analysis of the inherited iron metabolism disorders has identified many of
the proteins necessary for systemic iron homeostasis (Hentze et al., 2004; Pietrangelo,
2006b) (Figure 6). Ferrous iron (Fe2+) is taken up into cells by the divalent membrane
transporter DMT1, whereas ferric iron (Fe3+) enters cells via endocytosis of the
transferrin receptor following binding to transferrin (Andrews and Schmidt, 2007). The
most compelling feature of systemic iron homeostasis is that iron requirements far exceed
the gastrointestinal absorption capacity, and thus almost all the iron utilized each day is
continuously recycled from internal stores (Koury and Ponka, 2004) (Figure 7). Central
to this process is the hepatocyte-derived peptide hepcidin, which regulates iron
availability in response to hypoxia, inflammation, erythropoietic needs, and iron stores
(Nemeth and Ganz, 2006). Hepcidin binds to and induces the endocytosis and turnover of
the plasma membrane iron exporter ferroportin, which is the primary determinant of
gastrointestinal iron absorption and iron release from reticuloendothelial stores (Nemeth
et al., 2004). Ceruloplasmin plays a critical role in this process by establishing a rate of
plasma iron oxidation sufficient for the continued release of this metal from the storage
sites (Harris et al., 1998) (Figure 7).
Iron is taken up into the brain from the plasma via transferrin receptor–mediated
endocytosis in the brain capillaries and returned to circulation via absorption of
cerebrospinal fluid (Moos et al., 2006). Brain iron accounts for less than 2% of the total
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body iron content and varies greatly in amount and concentration depending on the
specific region of the brain. The concentration of iron in the brain is greatest in the basal
ganglia where it is equivalent to that found in the liver, suggesting a role in brain iron
storage and distribution (Haacke et al., 2005). Iron is widely distributed in all cell types
within the central nervous system but is abundant especially in astrocytes, supporting the
idea that these cells and other types of glia function in iron storage and regulation.
Iron requirements in the brain are much greater than the observed rate of iron
uptake into this tissue (Bradbury, 1997). This finding suggests most brain iron used each
day is derived from recycling behind the bloodbrain barrier analogous to what occurs in
the periphery (Figure 7). This mechanism would protect the brain from the effects of
systemic iron overload or deficiency and is supported by observations that disturbances
of systemic iron homeostasis exhibit minimal effects on central nervous system iron
content or metabolism (Moos and Morgan, 2004). The rate of brain iron uptake is greatest
during fetal life and postnatal iron repletion is ineffective to correct the cognitive defects
arising from iron deficiency in utero; this concept indicates that following birth recycling,
rather than uptake from the circulation, is the major iron source for brain function (Lozoff
et al., 2006). Existence of this brain iron cycle has critical implications for interpreting
any finding of brain iron accumulation in disease. The inherited disorders
aceruloplasminemia and neuroferritinopathy support the concept of a brain iron cycle and
demonstrate that dysregulation of brain iron homeostasis can be a primary cause of
neurodegeneration (Ponka, 2004) (Table 3).
Aceruloplasminemia
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Aceruloplasminemia is an autosomal recessive disorder of iron homeostasis
caused by loss-of-function mutations in the ceruloplasmin gene (Harris et al., 1995;
Yoshida et al., 1995). Patients have absent serum ceruloplasmin, decreased serum iron,
elevated serum ferritin, anemia, and insulin-dependent diabetes mellitus (Gitlin, 1998;
Nittis and Gitlin, 2002). Despite these systemic features, most patients present with
progressive dementia, dysarthria, and dystonia secondary to basal ganglia iron
accumulation (Logan et al., 1994; Miyajima et al., 1987; Morita et al., 1995). The
neurologic disease in aceruloplasminemia is always associated with increased brain iron
as detected by magnetic resonance imaging or autopsy (Kono and Miyajima, 2006).
Histological findings from affected brain regions include neuronal cell loss, abnormal
astrocyte architecture, and excess iron deposition in glia and neurons (Kaneko et al.,
2002; Morita et al., 1995; Oide et al., 2006) (Figure 4).
The absence of ceruloplasmin results in the slow accumulation of iron in the
reticuloendothelial cells where this metal is normally stored and then mobilized for
recycling (Harris et al., 1999; Patel et al., 2002) (Figure 7). This mechanism of systemic
iron accumulation also occurs in patients with dominant-negative mutations in the gene
encoding the iron exporter ferroportin (De Domenico et al., 2006). Loss of ceruloplasmin
also results in increased nontransferrinbound iron that rapidly accumulates in the liver,
pancreas, and other tissues following removal from the plasma by DMT1 (Andrews,
2002; Hentze et al., 2004) (Figure 7). This mechanism of tissue iron accumulation also
occurs in atransferrinemia, where the absence of serum transferrin increases the relative
amount of nontransferrin-bound plasma iron (Craven et al., 1987); in HFE
hemochromatosis, where excess iron absorption elevates nontransferrin-bound plasma
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iron (Andrews, 2002); in the thalassemias and other forms of secondary iron overload,
where transfusiondependency elevates nontransferrin-bound plasma iron (Pietrangelo,
2006b); and in hemochromatosis, owing to loss-of-function mutations in ferroportin that
impair hepcidin regulation inappropriately increasing nontransferrin-bound iron (De
Domenico et al., 2006).
Although these disorders of iron metabolism share common mechanisms of tissue
iron overload, accumulation of iron in the brain is unique to aceruloplasminemia. The
absence of brain iron accumulation in other diseases with increased nontransferrinbound
plasma iron supports the idea that brain iron accumulation in aceruloplasminemia results
directly from impaired iron homeostasis within the central nervous system. Consistent
with this concept, ceruloplasmin is synthesized in astrocytes (Klomp et al., 1996; Klomp
and Gitlin, 1996) as a glycophosphatidylinositol-linked isoform (Jeong and David, 2003;
Patel et al., 2000), suggesting that this membrane-bound ferroxidase facilitates the rate of
iron release from storage cells within the central nervous system. Ceruloplasmin is one of
very few proteins established as playing a critical role in brain iron homeostasis.
Neuroferritinopathy
Ferritin is a ubiquitously expressed cytoplasmic iron storage protein consisting of
heavy and light chains encoded on separate genes (Figure 6). Iron-dependent
translational regulation of this protein by the cytosolic iron regulatory proteins Irp1 and
Irp2 ensures that ferritin is a readily available source of intracellular iron in all cells
including neurons and glia (Rouault, 2006). Neuroferritinopathy, an autosomal dominant
extrapyramidal disease resulting from mutations in the gene encoding the light chain of
ferritin, has revealed a primary role for ferritin in brain iron homeostasis (Curtis et al.,
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2001; Maciel et al., 2005; Mancuso et al., 2005; Vidal et al., 2004). Pathological
examination of affected patients reveals cavitary degeneration in the basal ganglia nuclei,
neuronal loss, and iron and ferritin in both extracellular and cytoplasmic inclusion bodies
of microglia. The autosomal dominant inheritance and the multimeric structure of ferritin
suggest that these mutations impair ferritin assembly resulting in loss of iron storage
capacity within brain cells and subsequent iron-mediated cell injury (Levi et al., 2005).
Although there are some phenotype-genotype correlations specific to each light chain
mutation, all patients with neuroferritinopathy evidence dystonia in association with basal
ganglia iron accumulation (Chinnery et al., 2007).
Patients with neuroferritinopathy express the ferritin light chain mutation in all
cells yet evidence no abnormalities in systemic iron homeostasis with the exception of
decreased serum ferritin (Chinnery et al., 2007). This finding suggests either a unique
role for the ferritin light chain in some cell types within the brain or a greater sensitivity
of these cells to this form of iron-dependent injury. Although the mechanism of
neurodegeneration in neuroferritinopathy is unknown, the similar pathology to
aceruloplasminemia suggests a role for ferritin in the brain iron cycle and implies a
common iron-dependent mechanism of neurodegeneration in these two diseases (Figure
7). Recent studies in aceruloplasminemia suggest that neuronal loss in this disease arises
from iron deficiency secondary to impaired iron movement from astrocytes within the
brain iron cycle (Jeong and David, 2006). Support for a similar mechanism in
neuroferritinopathy comes from a murine model of Irp2 deficiency that impairs ferritin
regulation, results in iron accumulation within oligodendrocytes, and leads to
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neurodegeneration most likely from secondary neuronal iron deficiency (LaVaute et al.,
2001).
Friedreich’s Ataxia
Friedreich’s ataxia is an autosomal recessive disorder characterized by sensory
neuron, cerebellar, and cardiomyocyte degeneration (Durr et al., 1996) due to loss of
function of frataxin, a mitochondrial protein involved in inorganic iron-sulfur (Fe/S)
cluster biogenesis (Babcock et al., 1997). Although not specific to the brain, the effect of
impaired mitochondrial iron homeostasis on neuronal survival in this disease warrants
mention here. Mitochondrial iron is required for heme biosynthesis and for the generation
of Fe/S clusters that are prosthetic groups in many essential enzymes (Ajioka et al., 2006;
Lill and Muhlenhoff, 2006). Iron is imported into mitochondria by mitoferrin, a
transporter expressed in the inner mitochondrial membrane (Shaw et al., 2006), and exits
mitochondria largely in the form of Fe/S clusters (Rouault and Tong, 2005). Although
excess mitochondrial iron is detected in cardiomyocytes and sensory neurons from
affected patients (Puccio et al., 2001), impairment of heme and Fe/S cluster biosynthesis
is the likely proximate cause of neurodegeneration in Friedreich’s ataxia (Lill and
Muhlenhoff, 2006; Voncken et al., 2004).
Neurodegeneration with Brain Iron Accumulation
Neurodegeneration with brain iron accumulation describes a heterogeneous group
of patients with progressive neurodegeneration and iron deposition in the basal ganglia
(Gregory and Hayflick, 2005; Hayflick et al., 2003). Most of these patients present in
childhood with dystonia, dysarthria, and pigmentary retinopathy and have autosomal
recessive, loss-of-function mutations in the gene-encoding mitochondrial pantothenate
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kinase 2, an essential mitochondrial enzyme involved in coenzyme A biosynthesis
(Hayflick et al., 2003; Johnson et al., 2004; Zhou et al., 2001). The mechanisms of iron
accumulation and the role of iron, if any, in the pathogenesis are unknown. However,
these disorders deserve mention because recent studies reveal mutations in the gene
encoding a calcium-independent group VI phospholipase A2 in some children with brain
iron accumulation and neurodegeneration, suggesting a novel link between phospholipid
and iron metabolism in the brain (Morgan et al., 2006).
CONCLUSIONS
The inherited disorders of copper metabolism reveal copper’s essential role in
brain development and neuropsychiatric disease. The mechanisms of psychiatric disease
observed in patients with Wilson disease are of particular interest. Chelation is an
effective therapy in such individuals, indicating copper’s direct role in pathogenesis and
suggesting avenues for study that may be widely applicable to brain function and mental
health. Although elucidation of the genetic basis of Menkes andWilson diseases has
revealed much about the cell biology of copper metabolism, much more needs to be
learned about the normal mechanisms of copper homeostasis in the brain. In particular,
the role of the basal ganglia in copper and iron storage and distribution needs further
study as do the mechanisms of this brain region’s vulnerability to excess copper and iron.
Recent studies have focused on copper’s role in the pathogenesis of prion-mediated
encephalopathy and Alzheimer disease, including the proposed treatment of affected
patients with metal chelating drugs (Bush, 2000; Doraiswamy and Finefrock, 2004; Gaeta
and Hider, 2005). However, caution is warranted because more knowledge of copper
homeostasis within the brain and copper’s role in specific neurologic functions is
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required before any such therapeutic approaches can be thoughtfully undertaken or
interpreted.
The discovery of aceruloplasminemia and neuroferritinopathy demonstrates that
dysregulation of brain iron homeostasis can be a primary cause of neurodegeneration.
These inherited disorders provide a platform for further mechanistic investigations that
should reveal new insights into brain iron homeostasis. Nevertheless, absent further
understanding of the molecular mechanisms of iron homeostasis in the central nervous
system, investigators currently cannot interpret the significance of iron accumulation in
the pathogenesis of other neurologic diseases (Lee et al., 2006; Zecca et al., 2004). This
concept is illustrated by recent studies in aceruloplasminemia that suggest that
neurodegeneration arises from iron deficiency despite the marked brain iron overload. A
cautionary tale is also provided by the numerous iron chelator and antioxidant trials
initiated in patients with Friedreich’s ataxia on the basis of the findings of mitochondrial
iron accumulation, none of which have any demonstrated clinical benefit in doubleblind
placebo-controlled trials. These data remind us of the need for critical, mechanistic
approaches to defining disease pathogenesis when normal physiology remains poorly
understood. In this regard, attention is given to recent studies identifying a signaling
cascade in neurons where stimulation of NMDA receptors mediates iron uptake via the
divalent iron transporter DMT-1. This work provides a physiologic link between neuronal
function and iron homeostasis and suggests mechanisms linking iron and NMDA
neurotoxicity that would direct future investigation (Cheah et al., 2006).
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Table 1
Genetics

Presentation

Defect
Pathogenesis
Clinical

Pathology

Wilson Disease
Autosomal recessive
Loss-of-function mutations
ATP7B gene
Late childhood: liver
Second-third decated,
neuropsychiatric
Biliary copper excretion
Copper accumulation
Cirrhosis, dystonia, dysarthria,
Parkinsonian tremor,
psychiatric
Basal ganglia copper
accumulation
Neuronal cell loss

Menkes Disease
X-linked
Loss-of-functions mutations
ATP7A gene
Early infancy

Copper transport across the placenta, brain, and
gastroinestinal tract
Copper deficiency
Hypothermia, hypopigmentation, abnormal hair,
tortuous arteries, intractable seizures, failure to thrive
Cerebral and cerebellar degeneration
Purkinje cell axonal swelling
Abnormal arborization

Table 1: The hereditary disorders of copper metabolism
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Table 2
Enzyme
Tyrosinase
Lysyl oxidase

Function
Melanin formation
Collagen and elastin cross-link
formation

Peptidylglycine αamidating monooxygenase
Cu/Zn superoxide
dismutase
Ceruloplasmin

Acitavtion of peptides with αterminal glycine
Antioxidant defense (superoxide
dismutation)
Ferroxidase

Hephaestin

Ferroxidase

Dopamine-β-hydroxylase

Norepinephrine synthesis

Cytochrome c oxidase

Oxidative phosphorylation

Table 2: The cuproenzymes
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Consequences of Loss
Albinism
Perinatal death: arterial aneurysms,
diaphragmatic rupture (Hornstra et
al. 2003)
Embryonic lethality: cardiac failure
(normal CNS) (Czyzyk et al. 2005)
Impaired pulmonay defenses to
paraquat; infertility (Ho et al. 1998)
Parenchymal iron overload, anemia,
diabetes, neurodegeneration
Impaired iron absorption, anemia
(Vulpe et al.1999)
Impaired sympathetic regulation,
hypotension, hypoglycemia
Encephalopathy, muscle weakness,
cardiac failure - neonate

Table 3
Genetics

Presentation
Defect
Pathogenesis
Clinical
Pathology

Aceruoloplasminemia
Autosomal recessive
Loss-of-function mutations
Ceruloplasmin gene
Third decade – diabetes
Fifth decade – neurologic
Brain iron recycling
Brain iron accumulation
Systemic iron accumulation
Diabetes, anemia, dementia,
dystonia, dysarthria
Iron accumulation in astrocytes
Neuronal cell loss

Neuroferritinopathy
Autosomal dominant
Dominant negative
Ferritin light chain gene
Third through sixth decade
Brain iron storage
Brain iron accumulation
Dementia, dystonia, dysarthria
Iron accumulation in astrocytes
Neuronal loss

Table 3: The hereditary disorders of brain iron metabolism
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Abstract
Although the molecular basis of many inherited metabolic diseases has been defined,
the availability of effective therapies in such disorders remains problematic. Menkes
disease is a fatal neurodegenerative disorder due to loss-of-function mutations in the
ATP7A gene encoding a copper transporting P-type Atpase. To develop novel therapeutic
approaches in affected patients we have identified a zebrafish model of Menkes disease
termed calamity that results from splicing defects in the zebrafish orthologue of the
ATP7A gene. Embryonic recessive lethal mutants have impaired copper homeostasis that
results in absent melanin pigmentation, impaired notochord formation and hindbrain
neurodegeneration. In this current study we have attempted to rescue these striking
phenotypic alterations utilizing a series of antisense morpholino oligonucleotides directed
against the splice-site junctions of two mutant calamity alleles. Our findings reveal a
robust and complete correction of the copper-deficient defects of calamity in association
with the generation of wild-type Menkes protein in all rescued mutants. Interestingly,
quantitative analysis of atp7a specific transcripts suggests that competitive translational
regulation may account for the synthesis of wild-type protein in these embryos. This in
vivo correction of Menkes disease through rescue of aberrant splicing may provide new
therapeutic options in this fatal disease and illustrates the potential for zebrafish models
of human genetic disease in the development of treatments based on the principles of
interactions of synthetic oligonucleotide analogues with mRNA.

Introduction
Menkes disease is an inherited metabolic disease due to loss of function mutations in
the ATP7A gene encoding a P-type Atpase required for copper absorption and
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homeostasis (Lutsenko et al., 2007; Lutsenko and Petris, 2003). Patients with Menkes
disease have absent melanin pigmentation, impaired extracellular matrix formation and
neurodegeneration resulting in intractable seizures, hypotonia, severe failure to thrive and
death in early infancy (Culotta and Gitlin, 2001b; Kaler, 1998). These pleiotropic
phenotypes result from loss of activity of essential cuproenzymes within distinct
subcellular compartments. Treatment with exogenous copper is largely ineffective
(Sheela et al., 2005) and absent development of directed pharmacotherapy, restoration of
normal gene function remains the most viable treatment for affected patients. While
partial correction of a murine model of Menkes disease was demonstrated utilizing a
human Menkes transgene (Llanos et al., 2006), methods of safely introducing wild-type
cDNAs into humans have remained elusive.
We recently utilized chemical genetics to obtain calamity, a zebrafish model of
Menkes disease (Mendelsohn et al., 2006). Embryonic mutants reveal a striking
phenotype with absent melanin pigment, impaired notochord formation and
neurodegeneration. As several calamity alleles arise from splicing defects in the zebrafish
orthologue of ATP7A, we reasoned that if normal splicing could be restored sufficient
wild-type message might be generated to rescue these defects. Furthermore, as previous
studies of copper nutrition in the zebrafish embryo revealed a hierarchy of temporal and
dosage-dependent phenotypes (Mendelsohn et al., 2006) unique therapeutic windows
might allow for long-term correction following transient restoration of wild-type
expression. Such an approach has broad applicability as many metabolic diseases arise
from mutations that interfere with normal splicing of pre-mRNA message (Wang and
Cooper, 2007). In such cases the threshold of wild-type transcript necessary to restore
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functional protein may require only a small shift in favor of the wild-type message in
order to ameliorate the disease.
RNA targeting has recently emerged as a potential alternative to more conventional
approaches in gene therapy (Wood et al., 2007). Antisense oligonucleotides which bind
to pre-mRNA and sterically alter processing have been used successfully in cell culture to
demonstrate the utility of this approach (Bruno et al., 2004; Du et al., 2007; Gebski et al.,
2003; Suwanmanee et al., 2002). More recently, in murine models of Duchenne muscular
dystrophy, systemic delivery of morpholino oligonucleotides has been shown to effect
partial restoration of protein function on a cellular level in mutant mice (Alter et al.,
2006; Lu et al., 2005; Moulton et al., 2007). A critical factor in such strategies for the
treatment of human metabolic disorders is the availability of robust disease models that
permit rapid screening for effective phenotypic rescue. In this current study we have
utilized such an approach to rescue the phenotype of calamity, demonstrating the
applicability to complex organisms of several recent cell culture studies using this
technology in a number of human genetic diseases (Du et al., 2007; Moulton et al., 2007;
Ugarte et al., 2007).

Results and Discussion
Recently, our lab has described the zebrafish mutant calamity (allele vu69) as a
model of Menkes disease that recapitulates key aspects of the human phenotype
(Mendelsohn et al., 2006) (Fig. 1A). The defect in calamityvu69 is caused by creation of a
new 3’ splice site resulting in a 7 base-pair insertion into the mRNA (Fig. 1F). The
subsequent frame-shift creates an early stop codon and loss of greater than 95% of the
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protein product (Fig. 1 D,E). In the course of continued screening we have identified a
second allele of calamity, designated gw246. This allele causes an identical phenotype to
the first and is non-complementary in a standard genetic cross (Fig. 1 B, C). Cloning of
the mRNA in this mutant revealed a 12 base-pair in-frame deletion at the 3’ end of exon
20 which removes 4 amino acids located in the critical and highly conserved ATPase
domain of Atp7a (Fig. 1F). This deletion at the junction of two exons is due to the
preferential use of a new 5’ splice site. Interestingly, genomic sequence analysis revealed
mutation of neither the wild-type 5’ splice site (splice donor) nor creation of a new GT
splice donor pair; rather, the mutation was five base-pairs downstream from the new
mutant splice donor. Comparison of the mutant sequence to the previously established
zebrafish splice donor consensus sequence indicated that a new splice consensus site had
been formed (Yeo et al., 2004). Given that the mutant displays such a severe phenotype
we inferred that this new consensus sequence creates a dominant splice donor to the near
exclusion of the wild-type donor. High-resolution separation of a small PCR product
from mutant cDNA demonstrates that this is indeed the case (Fig. 2B, lane 1). In this
mutant, any wild-type splicing that does occur retains a single base change which causes
a non-conservative amino acid change from Leu to Arg at position 1316 (Fig. 1F).
Immunoblots with an antibody raised against a C-terminal peptide from zebrafish Atp7a
revealed near-complete loss of protein product in both vu69 and gw246 (Fig. 1E). This
lack of protein product in the gw246 allele suggests that there may be an early processing
defect which causes rapid and early degradation of the protein.
The presence of the wild-type splice sites in both alleles of calamity immediately
caused us to consider the use of morpholinos directed to specific sequences near the
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mutant splice sites in a bid to “force” wild-type splicing events. There was no data
available indicating the precise location that would be best suited for accomplishing this
goal. At the same time, the nature of both alleles provided an ideal system for
investigating this very question. In the case of gw246 we had two competing splice
donors sufficiently far apart that we might interfere with one or the other but close
enough that we might also block both.
Design of a series of morpholinos that would “walk” along the exon-intron
boundary sequence was based on comparison with known consensus sequences (Fig.
2A). The basic 5' splice site consensus sequence is small and well defined making
targeting straightforward for the gw246 mutant (Yeo et al., 2004). Wherever a
morpholino sequence overlapped a mutation, the mutant sequence was used at that base
pair. The first series of morpholinos were injected at a dose of 1.44 pmol/embryo
(12ng/embryo) into intercrosses of gw246 heterozygous carriers. At 48hpf embryos were
examined for phenotypic effects and mutants collected for mRNA extraction and RTPCR. The effects on splicing are shown in Fig. 2B. Across the series of morpholinos
several splice forms were seen. We confirmed that each band is a splice form of atp7a via
direct sequencing of the RT-PCR product. Several patterns emerged from these
experiments. First, and most interesting, blocking of the mutant splice donor did indeed
restore a significant amount of wild-type splice product (lanes e2-e3); however, this was
not accompanied by a rescue of the phenotype. We surmised that this was due to the
retention of a single base change caused by the mutation in the final, properly spliced
transcript which results in the non-conservative L1316R substitution. Such a large change
in polarity and charge in a highly conserved region of this ATPase might be expected to
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disrupt function. Consistent with this hypothesis, when we introduced this mutation into
the wild-type cDNA it resulted in an ATPase that fails to deliver copper to tyrosinase in
transiently transfected ATP7A-deficient fibroblasts indicating that this mutation results in
an inactive transporter (Sup. Fig. 1). Alternatively, the mutation may render the protein
unstable leading to early degradation and subsequent loss of function.
Second, injection of the series of morpholinos revealed several other weak cryptic
splice sites all contained within exon 20, immediately 5’ to the mutation (Fig. 2). This is
most clearly seen when the morpholino overlies both the wild-type and mutant sites
(lanes e4-e5). There was no evidence of exon skipping induced by any of the
morpholinos (data not shown). Bands corresponding to inclusion of the entire intron in
the final product were seen, but we could not totally rule out the possibility of genomic
contamination of the cDNA as the source of these bands (data not shown).
Thirdly, the morpholino that accomplished the most robust rescue of mRNA
splicing (lane e3) overlay the mutant splice site on either side and remained at least 6
base-pairs 5' to the wild-type GT pair. Moving only four bases in either direction resulted
in either an increased use of the mutant site or an increase in the upstream cryptic sites
due to blockage of the wild-type and mutant sites (lane e4-e5).
Lastly, when the morpholino target sequence was located 3’ to the mutant splice
donor the mutant again became the dominant splice form (lane e7). Wild-type embryos
injected with this same morpholino fully displayed the calamity phenotype (Sup. Fig.
2B). Combined with the RT-PCR data this indicates that when the wild-type 5’ splice site
is blocked by a morpholino the next most robust cryptic site is the one used in the mutant.
Injection of wild-type embryos also resulted in the same pattern of splicing illustrating
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why the mutation is so easily capable of co-opting splicing to the cryptic site in the
mutant (Sup. Fig. 2A).
These specific observations on a trial-and-error approach allow us to propose a set
of generalities regarding morpholino targeting to an exon-intron junction. First,
morpholinos targeted within 30bp of an 5’ splice site will have an effect on splicing, even
if it is subtle. Secondly, in some cases it appears that the magnitude of the effect of the
morpholino is dependent not only on its distance from the splice site, but also upon the
general strength of the splice consensus (cf. e1 and e4) and surrounding cryptic sites.
Thirdly, optimal blocking occurs in two forms: 1) the morpholino is entirely exonic
except for 2bp overlap with the GT pair (e2 and e5), or 2) the morpholino extends at least
6 bp on either side of the exon-intron junction. Fourthly, morpholinos can reveal
unappreciated enhancers and suppressors of specific splicing events located outside of the
consensus sequence (e10) and can be used to change the hierarchy of cryptic splicing
events. Validation of these rules will require separate experiments in a different mutant
with a similar defect and distinct phenotype; however, they do establish a framework
which can guide further testing.
Taken together these results demonstrate the utility of using morpholinos
to correct aberrant splicing in an embryonic vertebrate in cases where wild-type splice
donors are not affected. Morpholino e3 strongly rescues the mRNA. Unfortunately we
did not see a corresponding rescue of the phenotype. That this mutant protein was
incapable of rescue indicates one of the potential caveats of this system – that the
retention of a mutation in the rescued mRNA can just as strongly affect the phenotype of
the organism as the mis-spliced sequence. Promisingly however, it has been estimated
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that the probability that a random amino acid change would cause protein inactivation is
around 34% (Guo et al., 2004). Conversely, this would mean that just under two-thirds of
random amino acid changes will result in functional protein sequence. Together with
alternate approaches such as forced exon skipping the probability of rescuing any given
splice mutation with morpholinos remains fairly high.
Unlike the gw246 allele, rescue of vu69 would not cause inclusion of the mutated
base but would fully restore the wild-type sequence without alteration. Also unlike
gw246 the mutation alters the splice acceptor. The length and placement of consensus
splicing sequences around the splice acceptor are much less well defined and more
degenerate making targeting predictions much more cumbersome (Yeo et al., 2004).
Given the proximity of the vu69 splice acceptor to the polypyrimidine tract, we reasoned
that directly overlapping the mutant splice acceptor with a morpholino would interfere
with wild-type splicing. Similarly, we assumed that both mutant and wild-type splice
acceptors would use the same polypyrimidine tract, making it difficult to preferentially
target one splice acceptor by direct targeting of the polypyrimidine tract. However, the
inherent degeneracy of the U2AF recognition sequence might permit a morpholino
placed nearby to sterically interfere and alter the exact location of binding of the U2AF to
the polypyrimidine tract (Sickmier et al., 2006). No structural data existed to aid in the
design of such a morpholino. Therefore, we took a similar approach using a series of
morpholinos that “walk” across the splice acceptor region but expanded our target area to
include sequence up to 73 base-pairs 5’ to the mutant acceptor (Fig. 3A). Briefly,
morpholinos i1 and i2 both caused a more severe phenotype in calamity mutants and
heterozygotes implying an interference with wild-type splice events (Data not shown).
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Morpholinos i5 to i7 had no effect on phenotype. Morpholinos i3, i3.5 and i4 caused
robust rescue of the phenotype of mutant calamity embryos (Fig. 3B-G). Melanin
pigmentation was restored and the notochord did not contain any discernible defects
compared with calamity mutant embryos. The rescue was seen in 100% of the mutant
embryos with all injected mutants containing at least a few melanocytes and 95% having
greater than 20; no injected mutant embryo had a discernable notochord defect when
scored at 48 hpf (Fig. 3H). The rescue effect was still clearly visible at 6 days post
fertilization when about 75% of the uninjected calamity embryos were either dead or
dysmorphic (Fig. 3I) compared with nearly normal looking rescued embryos (Fig. 3J).
Lowering the dose of the morpholino resulted in similar pigmentation with intermediate
notochord defects consistent with previous observations on the developmental hierarchy
of copper metabolism that revealed a critical threshold of lysyl oxidase activity necessary
for normal notochord development (data not shown) (Gansner et al., 2007b; Mendelsohn
et al., 2006). Sequencing of genomic DNA confirmed that the rescued embryos were
indeed mutant (Data not shown).
As the mutant embryos had clear phenotypic rescue we wanted to confirm that
this was the result of restored protein expression. Immunoblot analysis of injected and
rescued mutants with a zebrafish Atp7a-specific antibody shows the restoration of fulllength, wild-type protein in the rescued embryos compared with no visible protein in
uninjected mutants (Fig. 4A). To our surprise however, this did not correspond with an
increase in wild-type splice products as measured via qRT-PCR . Only three consistent
patterns emerged from these experiments. The first is the presence of a small amount of
amplifiable wild-type transcript in all of the mutants, consistent with the presence of a
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wild-type band when end-point RT-PCR products are run on a polyacrylamide gel (Fig.
4C and Sup. Fig. 3B,C). The second is that there is decreased total atp7a transcript in the
mutants probably due to nonsense-mediated decay of mutant transcripts (Sup. Fig. 3D).
The third is that there is a significant reduction of mutant transcript in the injected
embryos. The most likely explanation for this reduction is the shifting of this transcript to
a third splice form, which is corroborated by the RT-PCR gel analysis showing a third
splice form containing an 800bp intronic insertion due to the use of a cryptic 3’ splice site
within the intron (Fig. 4C). Sequence analysis of the alternate splice form indicates a
frame shift and early stop codon, analogous to the original mutation. It is important to
note that as the antibody used for immunoblot recognizes the C-terminus of the wild-type
zebrafish protein, the identification of full-length protein will only occur when wild-type
transcripts are present.
Both the reduction in mutant transcript as well as the lack of any increase in wildtype transcript levels as measured by qRT-PCR were consistent across three embryo
ages, 12, 24, and 48 hours post-fertilization (data not shown) indicating that there is not
an early correction of splicing that decreases as the morpholino is diluted during
development. The lack of a measurable substantial increase in wild-type transcript in
these studies could simply reflect the limits of quantitation for the threshold necessary to
result in rescue. If this is the case, then it suggests that only small changes in wild-type
mRNA can result in significant phenotypic improvement on an organismal level, at least
in the case of Menkes disease. Alternatively, the data suggest that the increase in protein
levels could result from removal of inhibition on translation of the wild-type transcript.
Such inhibition could arise from competition for translation from the mutant transcript, a
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concept that would be consistent with observations on translational competition in
Drosophila (Gebauer et al., 1999) and is supported by our finding that knock-down of
the mutant transcript best correlates with rescue of the calamity phenotype through
restoration of protein levels (Fig. 4). Although this proposed mechanism for the increase
in functional protein is not directly testable under these conditions, if plausible this
significantly broadens the applicability of the morpholino approach because it
demonstrates that loss of one particular mutant form may be sufficient to cause rescue of
protein function and phenotype, with only minimal increases in the amount of wild-type
mRNA.
Taken together, the data reported here have several implications of direct relevance to
the development of effective therapeutics in Menkes disease. Experimental (Gansner et
al., 2007a; Mendelsohn et al., 2006) and clinical observations in affected patients (Tang
et al., 2006) reveal that maintenance of central nervous system function in this disease is
prioritized under circumstances of limited copper availability or decreased ATP7A
function. This hierarchy of copper delivery suggests that prevention of the
neurodegenerative features in Menkes disease may be possible with therapeutic
interventions that result in a modest increase in ATP7A within a specific developmental
window. The in vivo rescue observed in these studies directly supports these
pathophysiologic concepts and raises the potential for in utero interventions in this
disease. The data in this paper demonstrate the utility of zebrafish for rapid screens to
identify specific antisense sequences effective in phenotypic rescue. While morpholino
delivery remains problematic, given the robustness of the assay reported here and the
increasing number of zebrafish models of human genetic disease (Ackermann and Paw,
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2003) these findings support further study of this technology in the development of
effective therapeutics for inherited metabolic disease.
Methods
Animal maintenance. Fish stock maintenance was performed according to institutionally
approved procedures. Embryos for experiments were obtained through in vitro
fertilization and incubated at 28.5C. Wild-type fish were AB strain. The mutant calamity
has been described previously (Mendelsohn et al., 2006). Mutagenesis of wild-type fish
was performed using the chemical mutagen ethyl nitrosourea (ENU). Mutants were
screened for the calamity phenotype comprising lack of pigmentation and notochord
defects. Putative mutants were crossed to calamity to verify allelism. These were then out
crossed to AB fish and grown to adulthood. Regions of genomic DNA containing
putative mutations were sequenced in both AB and WIK strains to rule out the possibility
of strain-dependent polymorphisms.

Morpholino Synthesis and Injection. Morpholinos were synthesized by GeneTools,
LLC. Morpholinos were dissolved to 2mM in water and stored at -80C. Injection of
morpholinos was performed on a microinjection apparatus (Harvard Instruments). A
constant volume (1.44nL) of morpholinos was injected at different dilutions of the stock
(1:2 to 1:10) to optimize the dose which gave the strongest phenotypic effect while
minimizing off-target effects.
Molecular cloning and PCR. Total RNA was extracted from embryos using the Trizol
reagent (Invitrogen). Random hexamer primed cDNA was synthesized using
SuperScriptIII according to manufacturer’s protocol (Invitrogen). PCR was performed
58

using Phusion DNA polymerase (Finnzymes). High-resolution separation of products was
performed on 10% TBE-polyacrylamide gels. All sequences were verified by direct
sequencing. The L1316R clone of zebrafish atp7a was generated from the wild-type
sequence using the QuickChangeII site-directed mutagenesis kit (Stratagene). The altered
clone was sequenced and other PCR errors excluded.

qPCR. qRT-PCR was performed using primers specific to either the mutant or wild-type
form of the Menkes transcript. This was accomplished by designing primers that were
complementary to the exon-exon junction affected in the mutant (Sup. Fig. 3A). The
following primer sequences were used: Common forward primer
ATGATGAGCTCCGGACAGAC. calamity specific reverse
GGAATGATCTTTTCCACCTGAG. Wild-type specific reverse
GGAATGATCTTTTCCACTGTCG. Total atp7a primers
TGGAGCTTGTGGTCAGAGG and AGGGCAACTGAAGCGTAGAG. Ornithine
decarboxylase primers ATCTGGATCTCCGTTTTGCT and
CCGTTTTACGCAGTGAAGTG. Primer efficiencies were calculated in triplicate for
each primer set using either wild-type or mutant cDNA respectively. Random hexamer
primed cDNA was synthesized using SuperScript III (Invitrogen) according to
manufacturer's protocol. Quantitative PCR was carried out on an iCycler (BioRad) with
iQ Sybr Green SuperMix (BioRad). Calculations were performed using the Pfaffl method
and each bar in the figures is the average of 3 to 5 individually prepared embryo RNA
samples. Relative to wild-type, all cal embryos had a 50% decrease in total atp7a
transcript (data not shown).
59

Immunoblots. Twenty to thirty 48hpf zebrafish embryos were gently homogenized in
sucrose homogenization buffer (250mM sucrose, 5mM Tris pH 7.4) plus protease
inhibitors (Roche) and then spun at 100,000rpm in a table-top Beckman ultracentrifuge
for 30 min. The pellet was then resuspended in 50L RIPA buffer. Alternatively, 48hpf
embryos were manually deyolked and homogenized directly in RIPA buffer. Equal
amounts of protein were loaded on 6% polyacrylamide gels. After transfer to
nitrocellulose, immunoblotting was performed using a rabbit polyclonal antibody raised
to a C-terminal peptide of zebrafish Atp7a. Anti-rabbit secondary antibody and ECL
reagents were purchased from Pierce and used according to manufacturer’s
recommendations.
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Abstract

Nutrient availability is an important environmental variable during development that has
significant effects on the metabolism, health, and viability of an organism. To understand
these interactions for the nutrient copper we used a chemical genetic screen for zebrafish
mutants sensitive to developmental copper deficiency. In this screen we isolated two
mutants which define subtleties of copper metabolism. The first contains a viable
hypomorphic allele of atp7a and results in a loss of pigmentation when exposed to mild
nutritional copper deficiency. This mutant displays incompletely penetrant skeletal
defects affected by developmental copper availability. The second carries an inactivating
mutation in the vacuolar ATPase that causes punctate melanocytes and embryonic
lethality. This mutant, catastrophe, is sensitive to copper deprivation revealing overlap
between ion metabolic pathways. Together, the two mutants illustrate the utility of
chemical genetic screens in zebrafish to elucidate the interaction of nutrient availability
and genetic polymorphisms in cellular metabolism.
Author Summary
Copper is an essential nutrient required for multiple biologic functions. Proper uptake,
transport, and excretion of copper are critical for use of this metal while reducing its
inherent toxicity. While several key proteins involved in this process have been
identified, there are still gaps in our understanding of copper metabolism – particularly
during early development. We have used zebrafish, a genetically useful animal model
system, to study genetic interactions with copper deficiency during development. We
treated mutant embryonic zebrafish with a chelator which reduces the level of available
copper and screened for mutants which displayed a copper deficient phenotype only in
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the presence of the chelator. We identified and characterized two mutants which advance
our understanding of copper metabolism during the early periods of development as well
as show an interaction between copper metabolism and another fundamental pathway,
that of proton transport. Our results expand our knowledge of copper metabolism and
illustrate the power of this type of genetic screen in zebrafish to elucidate mechanisms of
nutrient metabolism.
Introduction
Proper maternal nutrition is critical for early embryonic development. The Dutch
Famine Study examined the consequences of nutrient deprivation on developmental
outcome during severe food shortages near the end of the Second World War and clearly
demonstrated that inadequate nutrient availability during human gestation increases the
likelihood of developmental anomalies (Susser et al., 1998). From these initial
observations arose the well-recognized link between maternal folate supplementation and
the suppression of neural tube defects (Czeizel and Dudas, 1992). Despite overwhelming
epidemiologic data indicating the benefits of folate and other nutrient supplementation
we do not fully understand the genetics of predisposition to these abnormal
developmental phenotypes when faced with suboptimal nutrient levels. There are several
large difficulties in the study of these processes in mammals that have prevented faster
progress. The first is that the genetics of mammals has been cumbersome. The second,
and more important, is that development of placental animals occurs in utero making
rapid detection of developmental phenotypes difficult. Finally, controlling the level of
nutrient available to the developing embryo cannot be done with precision as it depends
both on the genetics of the mother and the embryo as well as maternal nutrition.
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Copper is an essential nutrient which when absent results in severe developmental
abnormalities. This is most clearly illustrated by Menkes disease (OMIM #309400), a
rare X-linked disorder of copper metabolism. Patients with Menkes disease have an array
of symptoms including seizures, neurodegeneration, hypopigmentation, and lax skin
which result from decreased copper incorporation into critical enzymes such as
dopamine-β-hydroxylase and lysyl oxidase (Menkes, 1988; Menkes et al., 1962). This
usually fatal disease is caused by mutations in a copper transporter, ATP7A
(NM_000052), which resides in the secretory pathway and is responsible for transport of
copper into this compartment. The Menkes gene product is also responsible for placental
copper transport. While patients complete in utero development apparently normally, it is
clear from biochemical studies at birth that there are significant defects that arise from
gestational copper deficiency (Kaler et al., 2008).
In order to study the effects of developmental copper deprivation our lab has
previously created a zebrafish model of severe copper deficiency (Mendelsohn et al.,
2006). High doses of the cell permeable copper chelator neocuproine cause embryonic
zebrafish to exhibit a Menkes-like phenotype with neurodegeneration, hypopigmentation,
and connective tissue defects. Isolation and cloning of the mutant calamity, which shared
these same characteristics, revealed a loss-of-function mutation in the zebrafish
orthologue of ATP7A (NM_001042720). In this current study we expand this model to
study the effects of induced genetic alterations on the developmental response to mild
copper deprivation. We describe two mutants sensitive to nutritional copper deficiency
that illustrate the potential power of this approach to overcome the limitations of studying
gene-nutrient interactions in vertebrate organisms and that define combinations of loss72

of-function mutations of known ion homeostatic pathways that result in aberrant
development.

Results
Copper Deficiency Screen
In order to elucidate the molecular genetics of copper metabolism we performed a
forward genetic screen for zebrafish mutants with enhanced sensitivity to subthreshold
copper deficiency. To control copper levels zebrafish embryos were treated with the cell
permeable copper specific chelator neocuproine which has been previously shown to
cause a copper-deficient phenotype including loss of pigmentation and notochord defects
at a dose of 1 to 10 M due to loss of cuproenzyme activity (Mendelsohn et al., 2006;
Smith and McCurdy, 1952). Prior to screening, a subthreshold dose of 100 nM
neocuproine was determined to cause no alteration in pigmentation in wild-type, haploid
embryos. We then used this concentration of neocuproine to screen clutches of haploid
embryos derived from F1 carriers of ENU-induced mutations. One half of each clutch
was placed in 100 nM neocuproine at 3 hours post fertilization (hpf) and allowed to
develop until 48 hpf when clutches were screened for loss of melanin pigmentation in
50% of the embryos (Figure 1A). Only those clutches which had loss of pigmentation at
100nM neocuproine but contained at least some pigmentation when untreated were
scored as mutant. In this pilot screen we examined 700 F1 females and found five
potential mutants. Seven hundred mutagenized haploid genomes at an estimated single
locus mutation rate of 1.1x10-3 represents approximately a 65-70% coverage of the
genome (Solnica-Krezel et al., 1994). Of the five potential mutants, four were confirmed
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as true mutants as defined by the transmission of the neocuproine sensitive phenotype to
the offspring. One of these mutants fit the “ideal” criteria (no defect in vehicle and
complete loss of pigment in 100nM neocuproine in 50% of the haploid clutch) as
illustrated in Figure 1A and subsequent analysis revealed important insight into the
intersection of genetics with sub-optimal copper nutrition in early development. A second
mutant reveals a role for proton transport in copper metabolism. The final two mutants
were similar in phenotype to the first but full analysis has not been completed.
The first mutant isolated from the screen displayed normal melanin pigmentation
when untreated but completely lost all melanin upon treatment with 100 nM neocuproine
(Figure 1 B, C). Crossing this mutant with calamityvu69 (cal) which bears an inactivating
mutation in the copper transport protein atp7a resulted in partial non-complementation.
The compound heterozygote had no melanin in the developing retinal pigment epithelium
(RPE) and normally distributed mild hypopigmentation over the rest of the body (Figure
1 D). Based on the partial non-complementation we tentatively assigned this mutant as an
allele of calamity, designated gw71.
The second mutant has a phenotype that is independent of neocuproine. Named
catastrophe, this mutant has normally distributed melanocytes that are small and punctate
(Figure 1E). Catastrophe (cto) is homozygous lethal at about 3 days post fertilization (3
dpf). The heterozygotes have no overt phenotype. In addition, cto homozygotes display
sensitivity to copper deficiency by losing all melanin pigmentation in 100 nM
neocuproine (Figure 1F). Crossing cto with calvu69 results in complete complementation
(Figure 1G) including the observation that the double heterozygote is not more sensitive
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to neocuproine than calvu69 heterozygotes (data not shown). Thus, we continued our
analysis on the basis that cto identifies a new locus involved in copper metabolism.

A hypomorphic allele of atp7a
Chromosomal localization using the early pressure parthenogenesis method
(Johnson et al., 1995) placed the mutation in calgw71 (referred to below as gw71) near the
centromere of chromosome 14, the known location of atp7a. Combining this data with
the partial non-complementation, we hypothesized that this mutant represented a
hypomorphic allele of atp7a and confirmed this by direct sequencing of the mRNA.
Mutant atp7a was cloned and displayed 100% identity with the published atp7a sequence
(NM_001042720) with the exception of a single base change present in both mutant
clones, T3182G, which results in a single, non-conservative amino acid substitution,
I1061S (Figure S1A). This mutation is located in a region highly conserved in copper
transporting ATPases and exchanges a hydrophobic amino acid for one that is polar and
hydrophilic (Figure 2A). This single amino acid change results in significant depletion of
the full-length protein in mutant embryos (Figure 2B).
To verify that this was the causative mutation in gw71, we performed an in vitro
activity assay for the protein using wild-type and mutant atp7a. Fibroblasts from patients
with Menkes disease which lack functional ATP7A were transfected with tyrosinase in
combination with either wild-type or mutant zebrafish atp7a created via site-directed
mutagenesis of the wild-type cDNA. These fibroblasts were then treated with increasing
doses of neocuproine, fixed, and stained for tyrosinase activity using L-DOPA. Activity
is dependent on both atp7a and tyrosinase cDNAs (Figure S1B and S1C). In contrast to
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zebrafish mutant embryos, equal amounts of wild-type and mutant Atp7a were obtained
via transfection in these fibroblasts (Figure 2D). L-DOPA staining of cells expressing
mutant cDNA was only mildly reduced when compared with wild-type (Figure 2D vs. E)
indicating that the mutant retains some transport function. Overnight treatment with 25
nM neocuproine resulted in complete loss of tyrosinase activity in fibroblasts transfected
with mutant, but not wild-type, atp7a though a reduction in staining was observed with
wild-type (Figure 2F, G). These data suggest that this single mutation in atp7a not only
affects steady-state protein levels but is also capable of reducing the functional capacity
of the protein, leading to sensitivity to copper deficiency.
The I1061S mutation is located in the intracellular loop which comprises the
ATPase domain of the transporter (Figure 2H). Dimitriev et. al. have previously
performed NMR spectroscopy on the homologous domain of the Wilson disease copper
transporter, ATP7B, in the presence and absence of bound ATP and have derived from
the resulting chemical shift data the residues important for ATP binding and hydrolysis
(Dmitriev et al., 2006). We mapped the same region of Atp7a onto their model by
sequence alignment (64% consensus, 49% identical) to better understand the potential
effect of this mutation on protein function. The mutation in calgw71 lies five amino acids
away from a critical ATP binding residue, E1064, which is highly conserved from yeast
to humans (Figure 2A and Figure S1D). While a mutation of a critical residue would be
expected to significantly alter ATP binding or hydrolysis, a non-conservative mutation in
the region of a critical residue might be expected to only slightly alter ATP
binding/hydrolysis through minor shifts in regional structure.

76

gw71 mutants display post-embryonic sensitivity phenotypes
Because the gw71 allele is homozygous viable, we were able to examine several
post-embryonic roles for atp7a. Adult homozygous mutant zebrafish placed in varying
doses of neocuproine did not display an overt sensitivity phenotype (data not shown).
However, further study revealed a maternal effect of this mutation on embryonic copper
metabolism. Homozygous mutant embryos derived from heterozygous females had a
normal quantity and distribution of pigmentation that was partially sensitive to 100 nM
neocuproine which abolished pigment in the retinal pigment epithelium (RPE) and
reduced pigment over the body of the fish (Figure 3A, B). In contrast, homozygous
mutant embryos derived from homozygous mutant females had no pigment in the RPE
and reduced pigment over the body; treatment of these embryos with 100 nM
neocuproine completely abolished pigmentation throughout the embryo (Figure 3 C, D).
The effect of the mother’s genotype on the embryonic phenotype indicates that though
not overt, the adult homozygous mutant does have defects in copper metabolism
demonstrated by a nutrient-deficient state in the offspring. Thus the sensitivity of the
embryo to neocuproine is due not only to aberrant embryonic copper metabolism, as the
embryos from heterozygous mothers are sensitive to copper deficiency, but also to a
deficient maternal loading of copper into the egg as the phenotype is exacerbated by
maternal homozygosity.
The importance of optimal copper nutrition during development is further
illustrated by the presence of vertebral skeletal defects in homozygous mutants.
Homozygous mutant embryos were stained at 21 dpf with alcian blue/alizarin red to
reveal bone and cartilage respectively. These were compared with wild-type syngeneic
77

age-matched controls raised in the same manner. The wild-type fish had straight vertebral
columns along the entire length with long, straight bony processes extending from each
vertebra (Figure 3E). In contrast, homozygous gw71 fish displayed variable vertebral
defects, most often a significant warping of the bony structures in the caudal-most region
of the column caused by irregular length of vertebrae and defects in the joint angles
(Figure 3F). In addition the bony processes were also shortened and bent. Consistent with
the observations in embryos that the mutation in gw71 brings the homozygous embryo
close to, but not over, a threshold for copper deficiency, the persistent skeletal defects in
the juvenile fish were not fully penetrant. Whereas wild-type fish had no vertebral defects
(n=26), a significant number (38%, n=60) of the gw71 fish contained defects (Figure 3G).
Incomplete penetrance of the defect in the homozygous mutant fish could be
attributed to either separate subtle genetic interactions or to variable nutrient availability.
We hypothesized that if the penetrance of the defects were based on nutrient availability
then reducing the nutrient levels would worsen the defects and increase the penetrance
and vice versa. We thus took gw71 mutant embryos and placed them in either normal egg
water or egg water supplemented with 100 nM neocuproine or 500 nM CuCl 2 from 3 to
51 hpf (48 hour exposure). In addition, two separate groups of embryos were treated
with neocuproine from 16 to 64 hpf and from 30 to 78 hpf to determine if there was a
window of developmental time critical for the genesis of later defects. At 21 dpf the
larvae were stained with alcian blue/alizarin red and scored for the presence or absence of
vertebral defects (Figure 3G). Untreated wild-type embryos (not shown) or wild-type
embryos treated with 100 nM neocuproine from 3-51 hpf had no perceptible skeletal
defects. Thirty-eight percent of gw71 embryos had skeletal defects and this number was
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not significantly affected by treatment with 100 nM neocuproine or 500 nM CuCl2 from
3-51 hpf. However, there was a 50% increase in the number of skeletal defects in gw71
embryos treated with 100 nM neocuproine from 16 to 64 hpf. The larvae treated with 100
nM neocuproine from 30 to 78 hpf died approximately 8 dpf from an unidentified cause.
These results indicate an increasing sensitivity to mild copper deprivation as the embryo
develops in the first 16-72 hrs. Further experimentation with smaller, more discrete
treatment times might allow the determination of any developmental window required for
the effects of copper on vertebral axis formation.
In addition to the presence of vertebral skeletal defects in fully ossified skeletons,
larvae at earlier stages of development displayed hyperossification of vertebrae adjacent
to defects in the vertebral column (Figure 3 H, I). Normal zebrafish bone ossification
begins rostrally and generally proceeds caudally with the exception of the caudal fin
vertebrae (Du et al., 2001). In gw71 this pattern is maintained (arrowhead in Figure 3 H)
except for areas containing defects (arrow in 3H). The defects affected the joints between
vertebrae and had differing degrees of connective tissue bulges which partially stained
with alcian blue indicating the presence of some cartilaginous tissue in these defects
(Figure 3H arrowhead).

catastrophe contains a defect in proton transport
Before mapping the catastrophe mutant it was important to determine the extent
of the defect in copper metabolism. The loss of pigmentation in the mutants could result
from toxicity in a “two-hit” model whereby the mutation damages melanocytes and the
drug acts to further affect these already sick cells. Therefore we examined the sensitivity
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of the mutant to another copper-dependent process – notochord formation. Notochord
formation requires the action of the cuproenzyme lysyl oxidase and its family members.
Both reduction in lysyl oxidase levels and copper chelation result in wavy, distorted
notochords (Gansner et al., 2007b). Placing cto mutants in 2 μM neocuproine at 3 hpf
resulted in wavy notochords in the mutant embryos at 24 hpf while having no effect on
heterozygous or wild-type embryos (Figure 4A, B). This experiment indicates that the
mutation in cto causes a global defect in copper metabolism and is not limited to
melanocytes.
The mutation in cto was localized to chromosome 7 and further mapping reduced
the region of interest to an approximately 1 Mbp region between markers z21519 and
z43308 (Figure 4C). It was possible to assemble a nearly complete BAC contig between
these markers using database BAC sequences (www.sanger.ac.uk/Projects/D_rerio/).
This contig was scanned for potential genes using the FGENESH program
(www.softberry.com) and comparing to the Ensembl database (www.ensembl.org). A list
of candidate genes was generated from this comparison. To further refine the list, a
database of zebrafish insertional mutants was scanned for mutants displaying a similar
melanocyte phenotype (Amsterdam et al., 2004). Approximately 6 mutants in this
database had punctate melanocytes, 5 of which had insertions in genes encoding subunits
of the vacuolar (H+) ATPase (Atp6) (NM_199620). As the critical region in cto contained
the d subunit of the V0 complex of the vacuolar ATPase we cloned and sequenced this
cDNA in the catastrophe mutants. A single base pair change C406T present in the mutant
resulted in a premature stop codon, Q136X (Figure S2). Sequence alignment with the
human sequences (NM_004691) revealed a highly conserved protein sequence (94%
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identical) that most closely aligned with the d1 subunit (Figure 4D). Further database
searches did not reveal a second d1 subunit in zebrafish.
The significant identity between the human and zebrafish protein sequences
allowed us to use an antibody directed against human ATP6V0D1 to examine the steady
state levels of protein. We hypothesized that the early stop codon would result in a
significant decrease in protein levels. Indeed, in 48 hpf embryos there is a near total
reduction in Atp6v0d1 protein as compared with wild-type embryos (Figure 4E). Total
loss of this highly conserved and essential protein (see below) may be the cause of the
catastrophe phenotype; however, there remains some possibility that another, tightly
linked mutation may contribute to the observed phenotype. Based on significant
experimentation in yeast a proposed quaternary structure for the vacuolar ATPase
complex has emerged (Figure 4F) (Kane, 1995; Kane et al., 1989; Smith et al., 2003;
Tomashek et al., 1997; Xu et al., 1999). In this model, the two main subcomplexes, V0
and V1 have complementary functions of proton translocation and ATP hydrolysis
respectively. The complexes are connected through several stalk subunits, v1d, v0d, and
v1f (not shown). Loss of these connecting subunits in yeast results in total loss of activity
of the complex (Bauerle et al., 1993). Thus in catastrophe, the loss of the v0d subunit
would be predicted to result in complete loss of proton translocation throughout the
embryo.

catastrophe is sensitive to pharmacologic inhibition of proton transport
If the defect in catastrophe is loss of Atp6 function the heterozygotes might be
sensitive to pharmacologic inhibition of this transporter. Consistent with this, wild-type
81

embryos placed at 24 hpf in 200 nM concanamycin A, a potent and specific inhibitor of
Atp6 (Huss et al., 2002), showed no apparent phenotype at 48 hpf (Figure 5A). However,
treatment of embryos heterozygous for cto resulted in punctate melanocytes and CNS
degeneration, resembling the mutant (Figure 5B). The mutants themselves appeared
qualitatively worse, with further reductions in melanocyte pigmentation and worsening of
the degenerative appearance (Figure 5C).

Secretory pathway copper transport is altered in catastrophe
While it is apparent that loss of Atp6 results in altered cuproenzyme activity for
two enzymes in the secretory pathway, it is unclear which step of global copper transport
is affected in cto embryos. To address this we performed transplant experiments to
determine the cell autonomy of the defect. Wild-type cells from actin::GFP transgenic
zebrafish were transplanted into cto embryos and examined at 48 hpf for pigmented cells
and GFP expression. Transplantation resulted in a few well-pigmented and stellate
melanocytes over the head and body as well as clusters of pigmented retinal epithelial
cells (Figure 5D). These same embryos were mosaic for GFP expression (Figure 5E). In
body melanocytes the melanin obscured GFP fluorescence (Figure 5E arrowhead). In
contrast, the retinal pigment epithelial melanocytes display GFP fluorescence in the
central area not covered by melanin (Figure 5E arrow). From this we make two
observations: First, the melanized melanocytes are derived from wild-type donor cells,
and secondly, that nearby wild-type epidermal cells are not required for normal melanin
pigmentation nor stellate appearance (Figure 5E arrowhead). Thus copper metabolism
must not be significantly disrupted on an organismal level, as these wild-type
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melanocytes in a mutant host still receive adequate copper for normal pigmentation. Also,
the stellate appearance indicates that the defect that causes punctate pigment cells in cto
is also cell-autonomous.
The transplant experiment addresses delivery of copper to each cell, but the
uptake or distribution of copper within the individual cell could also be affected in cto
embryos. We hypothesized that disruption of the transporter responsible for secretory
pathway acidification would result in defects in copper metabolism in this compartment.
To test this we examined the sensitivity of cto embryos to partial loss of Atp7a through
the use of a morpholino. Previous work from our laboratory has demonstrated that
melanin synthesis following loss of Atp7a is also cell-autonomous in the melanocyte
indicating that knock-down of Atp7a will allow interrogation of the pathway on a cellular
rather than organismal level (Mendelsohn et al., 2006). Injection of a splice morpholino
previously shown to result in a copper deficient phenotype at a dose that does not cause
pigmentation defects in wild-type or heterozygous embryos (Figure 5F) causes total loss
of melanin pigmentation in cto embryos (Figure 5G). Thus cto embryos are sensitive to
loss of the secretory pathway copper transporter, Atp7a. Embryos heterozygous for the
cto mutation did not show sensitivity to the Atp7a morpholino indicating that near
complete loss of Atp6 activity is required to sensitize to alterations in copper metabolism.
At the same time, the cytochrome oxidase activity of mitochondria derived from cto
embryos is no different from wild-type indicating that copper delivery to mitochondria is
normal and that the defect in copper metabolism in cto embryos is limited to the secretory
compartment (Figure 5H).
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Subcellular morphology and melanosome formation is altered in catastrophe
The vacuolar ATPase has been implicated in diverse trafficking events within the
cell and inhibition of this protein results in altered ion homeostasis, disrupted membrane
trafficking, defective acid secretion, deficient protein degradation, and loss of protein
sorting, endosomal recycling, and vesicular secretion (Dettmer et al., 2006; HurtadoLorenzo et al., 2006; Liegeois et al., 2007; Lin et al., 2006; Malikova et al., 2004;
Taupenot et al., 2005; Tawfeek and Abou-Samra, 2004). To examine the effect of loss of
this protein on cellular morphology, specifically melanocytes, we performed transmission
electron microscopy focusing on the pigmented cells. Thin (500 nm) plastic sections of
48 hpf embryos stained with toluidine blue did not demonstrate any further gross defects
in organismal or cellular morphology beyond those observed in the pigmented cells both
of the epidermis and the retinal pigment epithelium (data not shown). Upon examination
by electron microscopy in wild-type embryos both epidermal pigment cells as well as
retinal pigment epithelial cells at 48 hpf display dark, uniformly round or ellipsoid
melanosomes distributed throughout flat melanocytes (Figure 6A-C). In contrast, the
melanocytes of cto embryos are rounded and contain few fully melanized melanosomes,
many large vacuolated structures and small vesicles surrounded by rings of melanin
pigment (Figure 6D-F). These latter structures have been identified as multi-vesicular
bodies, the accumulation of which is reminiscent of early blocks in melanosome
maturation found in the cappuccino, pallid, ruby-eye 2, and reduced pigmentation mice
which are all models of Hermansky-Pudlak syndrome and have specific early defects in
melanosome biogenesis (Nguyen et al., 2002). Thus among other abnormalities loss of
proton transport results in early blocks in melanosome maturation. It is interesting to note
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that there remains active tyrosinase which produces some melanin in these aberrant
structures despite the loss of the proton transporting ATPase (Figure 6F).

Discussion
Genetic screen for gene-nutrient interactions
In this work we have used the power of forward genetic screens combined with
the ease of ex utero nutrient level manipulation accessible with the zebrafish to study the
relationship between specific genetic alterations, the levels of the essential nutrient
copper, and their combined effects on the developmental phenotype of the embryo. From
these experiments we have derived a nutrient-sensitive allele of a known copper
transporter that results in a juvenile skeletal phenotype. We have also implicated the
vacuolar proton pump in vertebrate copper metabolism and interconnect two ion transport
proteins whose individual effects on the other would not otherwise have been
appreciated.
The ex utero development of zebrafish provides an opportunity for manipulating
the developmental levels of nutrients. Much success has been achieved in yeast using
large libraries of compounds coupled with known deletion mutants to define the roles of
many of the yeast proteins in cellular biology and metabolism (Hillenmeyer et al., 2008;
Parsons et al., 2004). One major advantage of yeast is the ability to absolutely control the
levels of different nutrients and pharmacologic compounds and to screen large numbers
at a time; however, yeast lack the complexity necessary to extend such findings to multicellular organisms and ultimately to understand human biology for the treatment of
disease. Our work shows that the zebrafish model system can fill the niche in extending
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the principles of the chemical genetic screen to a vertebrate organism. Zebrafish retain
the advantage of environmental exposure control while only slightly reducing the ability
to screen large numbers. They also provide a system with more complex phenotypes to
be examined which can then be brought back to the study of the underlying cell biology
of a multi-cellular organism, particularly as the genome sequence and rapid mapping
techniques improve.

Nutrient-sensitive hypomorphic allele
The first mutant which was isolated from our screen was a hypomorphic allele of
atp7a. Animals bearing this allele have a normal pigmentation and notochord phenotype
at 48 hpf but are sensitive to mild copper deficiency thus indicating that transporter
function was impaired. This mutation reduced the protein levels to below the detection
limits of our immunoblot demonstrating that only a fraction of wild-type protein
expression is necessary to maintain a near-normal phenotype. This is consistent with our
previous observations where very minor changes in Atp7a protein levels resulted in
significant rescue of the calamity phenotype (Madsen et al., 2008). Also, the increase in
severity of the calvu69 allele upon incubation with neocuproine demonstrates that even in
this model of severe Menkes disease, there is still residual protein function without
detectable expression (Madsen et al., 2008; Mendelsohn et al., 2006). Interestingly, when
the gw71 protein was overexpressed in cell culture fibroblasts it was fully capable of
loading copper into the secretory pathway as evidenced by the robust tyrosinase activity;
yet, at the same time there was a clear sensitivity of this mutant transporter to copper
levels.
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This mutant allele is not the first hypomorphic allele of atp7a. A less severe form
of Menkes disease, Occipital Horn Syndrome, is also caused by mutations in atp7a.
Children with this disease have many clinical problems similar to Menkes disease;
however, as this syndrome is not fatal in early life other abnormalities can be appreciated
including skeletal defects such as deforming hyperostosis and kyphoscoliosis (Horn and
Tumer, 2002). In this context the gw71 mutant provides several important advances.
First, within the screen itself it provides proof-of-concept that the screen design will
result in the identification of critical proteins involved in copper transport and
metabolism. Second, the gw71 allele is both viable and fertile which itself provides
distinct advantages. Third, this allele demonstrates that only a fraction of wild-type levels
of Atp7a protein are required for near-normal pigmentation and notochord formation, a
result suggested by previous experiments (Madsen et al., 2008). Fourth, this mutant
expands the hierarchy of copper metabolism previously described (Mendelsohn et al.,
2006). The differential effect on retinal pigment epithelial melanin versus the body
pigmentation seen under a variety of genetic and environmental manipulations (Compare
Figures 1D, 3B, and 3D) demonstrates an increased sensitivity of the RPE to
derangements of copper metabolism. Fifth, the gw71 mutant displays an incompletely
penetrant developmental hyperostosis phenotype which is easily detected. The proximal
etiology of these defects is unknown. It may be related to lysyl oxidase activity which is
important for zebrafish notochord development and is sensitive to nutritional copper
status (Gansner et al., 2007b). The increase in penetrance with copper chelation suggests
that the variability may be due to nutritional differences. The lack of rescue observed
with copper supplementation could be due to an inability of this ion to be translocated by
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the mutant Atp7a protein to the proper compartment. Alternatively, lack of rescue with
copper could point to residual genetic heterogeneity leading to phenotypic differences.
Whichever is the case, this aspect of the mutant phenotype may provide a model to
further our understanding of this poorly understood defect. The viability of this mutant
would allow a modifier screen to find mutations responsible for different aspects of the
copper deficient phenotype as well as to detect any genetic variability leading to the
incomplete penetrance observed in the mutant.

Intersection of two ion-transporting pathways
Our second mutant contains an inactivating mutation in the vacuolar (H+) ATPase
subunit, Atp6v0d1. While abolition of this protein results in loss of proton transport into
the secretory pathway, the embryo is capable of developing relatively normally to about
48 hpf when defects become visibly apparent. This lag is most likely due to the
persistence of maternal protein and mRNA. At this time point the changes in melanin
pigmentation patterns signal the visible presence of defects in proton transport. Grossly
the melanocytes become punctate which, upon ultrastructure analysis, is shown to be a
loss of mature melanosomes and a rounding of the cell body with vacuolization. The
observed relationship between lack of melanosome formation and cellular morphology is
not understood but may suggest a toxic effect of inappropriate melanization in the multivesicular bodies seen with electron microscopy or may be due to a particular sensitivity
of melanocytes to loss of proton transport. As it has been shown that the vacuolar ATPase
is important for vesicular trafficking and endocytosis (Dettmer et al., 2006; Hurtado-
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Lorenzo et al., 2006), the distinct disruption of planar morphology in cto melanocytes
may also be due to defects in these processes.
The sensitivity to copper deficiency of the remaining melanin implicates proton
transport in the homeostasis of copper metabolism. That the notochord is equally
sensitive to reduced copper demonstrates that the defect is not limited to the melanocyte,
but rather that there is a universal decrease in the ability of copper to adequately reach
secretory cuproenzymes. Since the effect on copper metabolism in cto mutants is only
revealed in the context of sub-threshold copper nutrition, without a screen of this nature,
this inter-relationship of two ion transport pathways in the vertebrate organism would
never have been appreciated.
There are two models which could explain the defect in cuproenzyme function
when proton transport is compromised. The first is that an acidic pH is important for
copper incorporation into the nascent cuproproteins within the secretory pathway. The
second model is that a proton gradient is required for copper transport, to balance the
charge transfer across the vesicular membrane. These models are not mutually exclusive
and a combination of the two could result in the final phenotype.
The data presented in this paper demonstrate the power of the zebrafish model
system to examine gene-nutrient interactions as well as to delineate basic cell biologic
pathways. Continuing with this methodology will provide more insight into the biology
of copper metabolism in a vertebrate organism. It is easy to see how screens in zebrafish
similar to the one we describe have the potential to investigate the genetics of not only
copper or folate metabolism, but also that this approach could be easily extended to an
array of other nutrients.
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Materials and Methods
Zebrafish Maintenance: Zebrafish were maintained in the Washington University
Department of Pediatrics zebrafish facility according to institutional guidelines
supervised by the Division of Comparative Medicine.
Mutagenesis, Screen and Mapping: The specific alterations of these well-characterized
techniques are available in the supplemental Text S1.
Immunoblot: Mutant 48 hpf embryos were identified phenotypically. Twenty to thirty
embryos were manually dechorionated and de-yolked, lysed in 75 μL RIPA buffer
containing 10 μL/mL Protease Inhibitor Cocktail III (Calbiochem). Unlysed material was
removed by centrifugation at 1000 x g for 5 minutes. For Atp7a, 50-100 μg of lysate in
Laemmli buffer with 10% β-mercaptoethanol, heating for 5 min at 65oC (not fully
reducing conditions) was loaded on a 6% SDS-polyacrylamide gel. The protein was
transferred to nitrocellulose and blotted for Atp7a using a custom polyclonal antibody
raised against a C-terminal peptide (Madsen et al., 2008). For Atp6v0d1, 30-40 μg lysate
in Laemmli buffer with 10% β-ME heated to 70o C for 5 minutes was loaded on a 12%
SDS-polyacrylamide gel. The transferred protein was blotted for Atp6v0d1 using a
mouse polyclonal raised to human recombinant protein at 1:1000 dilution (Abnova Corp).
Other antibodies: Actin (Sigma) 1:5000, β-catenin (BD Biosciences) 1:1000.
Me344 Cell Culture: The Menkes patient fibroblast cell line Me344 (gift of Mick Petris)
was maintained in 10% FBS/DMEM with Pen/Strep/Glut. Transfections were carried out
on coverslips using Lipofectamine 2000 (Invitrogen) at a ratio of Lipo2k:DNA of 2.5 for
3 hours in Optimem (Invitrogen). The media was then replaced with 1%
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FBS/DMEM/PSG. Neocuproine was added in DMSO to the indicated concentration and
the cells incubated overnight.
L-DOPA Staining: Performed as previously described (Petris et al., 2000).
Alcian Blue/Alizarin Red Stain: Twenty-one dpf juvenile zebrafish were fixed overnight
in 4% PFA in PBS and stained as previously described (Javidan and Schilling, 2004).
Transplantation: Approximately 50-100 cells were extracted from wild-type (AB)
embryos at the 1000 cell stage and placed in mutant embryos of the same age using a
micromanipulator syringe and glass needle as described previously (Westerfield, 2000).
Morpholino Injection: The atp7a splice morpholino e7
(TGACAACATTAACATTCATACCCTG) (Madsen et al., 2008) was injected at a dose
of 965 pg/embryo at the 1 cell stage in 10% phenol red. At 48 hpf the injected embryos
were scored for pigmentation and genotyped.
Cytochrome c oxidase Activity Assay: A crude mitochondrial fraction was prepared from
groups of 45 embryos at 52 hpf by homogenizing in 250 mM sucrose, 10mM Tris pH 7.4
with a loose-fitting glass-glass tissue homogenizer. The homogenate was spun at 700 x g
for 10 minutes. The supernatant from this spin was centrifuged at 23,000 x g for 20 min
to form a pellet containing mitochondria and large vesicles. The pellet was resuspended
in 150 μL of sucrose buffer with protease inhibitors and n-dodecyl-3-D-maltoside was
added to 1 mM and incubated for 10 minutes at 25o C. Cytochrome c oxidase activity was
monitored by measuring the decrease in absorption of ferrocytochrome c at 550 nm using
the protocol described for the Cytocox assay kit (Sigma, USA).
Transmission Electron Microscopy: Performed as described previously (Gansner et al.,
2007b).
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Supplemental Text
Supplemental Methods:

Mutagenesis: Male AB strain zebrafish at 12 weeks of age were placed in 3mM N-ethylN-nitrosourea (ENU) for 1 hour in the dark and then washed several times and allowed to
recover for one week. This was repeated for a total of 5 exposures. The mutagenesis rate
was monitored by crossing to nacre and scoring for mutant progeny. A rate of 1 nacre in
2000 embryos was obtained by this method. These mutagenized males were then crossed
to AB females to generate the F1 generation carrying a random array of ENU induced
mutations.
Screen: Clutches of eggs from F1 females heterozygous for random mutations were
obtained and fertilized with UV-inactivated sperm to create gynogenetic haploid
offspring (Fig 1A). At 3 hours post fertilization (hpf) half of each clutch was placed in
100nM neocuproine, a dose empirically determined to be a threshold dose for
pigmentation defects in wild-type AB haploid embryos in our egg water (35mg/L Crystal
Sea Marinemix, Marine Enterprises Int. Baltimore, MD with 18.3MΩ deionized water).
At 48 hours post fertilization clutches treated with neocuproine were scored for loss of
pigmentation. If the treated half of a clutch lacked pigment, the untreated half was
examined. If this half also lacked pigment the mutant was discarded; if it contained any
pigment at all, it was retained for characterization. F1 females from which mutant
clutches were derived were out-crossed to AB for maintenance and crossed to WIK strain
males for subsequent mapping. Mutants were confirmed by transmission of the
phenotype to subsequent generations.
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Early Pressure Parthenogenesis and chromosomal assignment: Gynogenetic diploid
mapping has been previously described (Johnson et al., 1995). Briefly, clutches of eggs
from heterozygous carriers were fertilized with UV-inactivated sperm and immediately
placed in a french press. At 1’20” a pressure of 8000psi was applied to the eggs and held
for 5 min. The embryos were then removed from the press and raised as normal larvae.
Simple sequence length polymorphisms (SSLPs, http://zebrafish.mgh.harvard.edu/) near
the centromere of each chromosome were used to assign the chromosome containing the
mutation, as mutants will have no recombination between the mutation and the
centromere. Also distance from the centromere is estimated based on the percentage
mutants in clutches derived in this manner.
Fine Mapping: Haploid embryos were obtained as above from heterozygous AB/WIK
females. At 48 hours post fertilization the embryos were sorted according to phenotype,
the DNA was extracted individually using proteinase K/phenol/chloroform and known
SSLP’s (http://zebrafish.mgh.harvard.edu/) were examined for linkage to the phenotype.
Cloning: Mutant atp7a was cloned and sequenced twice from a single cDNA preparation
using atp7a specific primers. Wild-type and mutant atp6v0d1 was similarly cloned using
the following primers based on the database sequence (NM_199620).

Allele-specific PCR: Detection of the ctogw325 mutation was accomplished using allelespecific PCR with the forward primer AAGCTTCCTGGCCAATGAAGC, the mutant
specific reverse primer GATGTTAACAGCCTCCATCTA, and a positive control reverse
primer CCAAATCCTGTTCAGAGATGC using a 62o C annealing temperature with
standard Taq polymerase (Promega).
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Conclusion
The studies described in this thesis have sought to elucidate the role of the critical
nutrient copper in the development of the vertebrate zebrafish embryo. Severe copper
deprivation caused by either nutritional deficiency or genetic deficiency results in several
developmental phenotypes that phenocopy the human gentic disease, Menkes disease.
Loss of cuproenzyme activity in either high-dose neocuproine treated embryos or in the
mutant calamity results in loss of pigmentation and notochord defects. These are
analagous to the hypopigmentation and basemement membrane defects observed in
Menkes disease. Using this robust model of developmental copper deficiency I have
sought to investigate further the genetics and cell metabolism of copper homeostasis.
Chapter 3 describes experiments which probe the possibility of early treatment of
Menkes disease through correction of splice defects in zebrafish embryos which carry an
inactivating mutation in atp7a. In human infants with Menkes disease there are subtle
defects even at birth (Kaler et al., 2008) and most die by age 3. This implicates the
protein in critical developmental processes. Also, it is possible that only a small amount
of protein product may be necessary for restoration of function as evidenced by the
disease Occipital Horn Syndrome. This latter disease is also caused by mutations in
ATP7A but is less severe than Menkes disease and patients often survive to adulthood. If
functional protein could be restored during early developmental periods, or if small
amounts of functional protein could be maintained, this could offer promising therapies
for severe Menkes disease.
Morpholino oligonucleotides alter splicing events via steric hindrance of the
splicing machinery and have been used previously in cell culture models to restore
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normal protein various diseases. This approach had not been demonstrated to rescue an in
vivo disease phenotype. We took advantage of two splice mutations in alleles of the
zebrafish mutant calamity (atp7a) to test the ability of morpholinos to functionally
correct splice defects and lead to rescue of the mutant phenotype. Through the use of a
series of morpholinos across an exon-intron boundary we investigated the effects of small
changes in targeting sequence on the ability of the morpholino to alter splicing. The
results demonstrated a set of principles of morpholino targeting to aid in the design of
further molecules. The lack of functional rescue in these experiments demonstrated one
of the limitations of the approach in that it is not capable of correcting point mutations
which might remain in the final mRNA depending on the specific splice mutation.
The same approach for an intron-exon boundary resulted in a similar set of useful
observations of targeting and the corresponding splicing effects. Three of the
morpholinos used were able to rescue the phenotpe of the mutant. Complicating the
analysis was the lack of observable change in the wild-type mRNA levels with
morpholino injection. There were significant shifts in the splicing profile to a second
upstream cryptic splice site which would also result in non-functional protein. The rescue
coupled with the difficulties in identifying the mechanism could have several
interpretations. The most probable, in my opinion, is that very little correct splicing is
required to generate enough protein necessary for partial function. This interpretation, if
correct, makes any therapy of this nature for this particular disease promising in that only
a small effect must be produced to have significant phenotypic amelioration. These
results also help explain the hypomorphic allele described above and discussed below.
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Chapter 4 describes the central part of this thesis, a genetic investigation of novel
mechanisms of copper homeostasis under conditions of limited availabilty. This screen
for mutants sensitive to copper deficiency was designed to use the phenotype of loss of
pigmentation to screen mutagenized zebrafish for proteins involved in copper
homeostasis. The combination of subthreshold doses of the chelator neocuproine and
genetic mutations increased the specificity of the screen for copper metabolic defects and
removed several pigment-only mutants from the analysis (2-3 out of 700). As we
expected we identified two types of mutants. The first was a hypomorphic allele of atp7a.
This mutation demonstrated the ability of the screen to identify proteins critical for
secretory-pathway copper homeostasis. If more mutants were screened we would expect
to also find the zebrafish orthologue of atox1. This mutant also revealed a maternal effect
of the mutation on embryonic pigmentation and expanded the hierarchy of copper
metabolism. A developmental skeletal phenotype characterized by premature ossification
of notochord defects in juvenile zebrafish mimics defects seen in both Menkes disease
and Occipital Horn Syndrome and further investigation might shed light on the
mechanisms of these skeletal deformities.
The second was a loss-of-function mutation in a critical subunit of the vacuolar
(H+) atpase (atp6v0d1). This mutant had its own distinct phenotype but was globally
sensitive to copper deprivation implicating the proton gradient within the secretory
compartment in the metabolism of copper. Genetic intersection with loss of atp7a
recapitulated the neocuproine phenotype demonstrating the specificity for particular
cellular compartments. Defects in intracellular morphology confirmed the role of this
protein in vesicle trafficking.
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Future Directions
These experiments have advanced our understanding of developmental copper
metabolism and provide a foundation and tools for further investigation. There are
several major ways in which this research could be expanded.
First, this was a relatively small screen of only 700 genomes. Further screening
would potentially result in the identification of more interesting mutants. The two
identified in this thesis demonstrated the sound nature of the screen approach and all that
remains is to continue. One would expect to find more interesting intersections of copper
homeostasis with other ion homeostasis as well as vesicular trafficking defects. We also
expected, but have not yet found, mild mutations in tyrosinase which would affect the
kinetics of copper loading into this enzyme. Such a mutant would expand our
understanding of the compartments in which copper is actually transported and the
mechanisms by which copper enters proteins once it is released into the secretory milieu.
Second, the identified hypomorphic allele opens another avenue for a similar
approach to the same question. A modifier screen in this genetic background would be
expected to find similar results as the neocuproine but might have the advantage of being
more specific. It is also possible that there are mechanisms that would be sensitive to loss
of copper with neocuproine but not with the weak allele, and vice versa. Thus this would
be a complementary approach to continuing the original screen.
Third, the hypomorphic allele also displays prominent notochord and skeletal
defects which give a model system to study the mechanisms of this process during
development. Both Menkes patients and Occipital Horn Syndrome patients have skeletal
deformities but it is unclear what the role of copper in these processes is. This allele
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represents a tractable model for studying this process, particularly as it relates to the
developing organism.
Fourth, the vacuolar atpase mutant has not been probed in depth for its effect on
other phenotypes. This protein has been implicated in many cellular processes and no
known knock-out exists. The ex utero development of the zebrafish embryo allows
visualization of complex processes and the relatively normal development to 48 hpf
might provide a system for evaluating the morphologic consequences of this type of
severe disruption of cellular homeostasis outside of copper metabolism.
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